Man  ||| S:454 E:458 ||| NN
made  ||| S:458 E:463 ||| VBD
peptide  ||| S:463 E:475 ||| VBN
Man  ||| S:946 E:950 ||| NN
made  ||| S:950 E:955 ||| VBD
peptide  ||| S:955 E:967 ||| VBN
Man  ||| S:1663 E:1667 ||| NN
made  ||| S:1667 E:1672 ||| VBD
peptide  ||| S:1672 E:1684 ||| VBN
Man  ||| S:1939 E:1943 ||| NN
made  ||| S:1943 E:1948 ||| VBD
peptide  ||| S:1948 E:1960 ||| VBN
Man  ||| S:2469 E:2473 ||| NN
made  ||| S:2473 E:2478 ||| VBD
peptide  ||| S:2478 E:2490 ||| VBN
Man  ||| S:2742 E:2746 ||| NN
made  ||| S:2746 E:2751 ||| VBD
peptide  ||| S:2751 E:2763 ||| VBN
Man  ||| S:4158 E:4162 ||| NN
made  ||| S:4162 E:4167 ||| VBD
peptide  ||| S:4167 E:4179 ||| VBN
Man  ||| S:6318 E:6322 ||| NN
made  ||| S:6322 E:6327 ||| VBD
peptide  ||| S:6327 E:6339 ||| VBN
Plasmid  ||| S:7084 E:7096 ||| UH
Plasmid  ||| S:11283 E:11295 ||| UH
Plasmid  ||| S:15778 E:15790 ||| UH
Diluent  ||| S:20903 E:20911 ||| NNP
for  ||| S:20911 E:20915 ||| IN
immunohistochemistry  ||| S:20915 E:20939 ||| FW
Hurley  ||| S:20967 E:20974 ||| NNP
John  ||| S:20974 E:20979 ||| NNP
K ||| S:20979 E:20980 ||| NNP
.  ||| S:20980 E:20983 ||| .
Tucson  ||| S:20983 E:20990 ||| NNP
AZ  ||| S:20990 E:20993 ||| NNP
US  ||| S:20993 E:20999 ||| NNP
Tucson  ||| S:21031 E:21038 ||| NNP
AZ  ||| S:21038 E:21041 ||| NNP
US  ||| S:21041 E:21047 ||| NNP
An  ||| S:21171 E:21174 ||| DT
embodiment  ||| S:21174 E:21185 ||| NN
of  ||| S:21185 E:21188 ||| IN
the  ||| S:21188 E:21192 ||| DT
invention  ||| S:21192 E:21202 ||| NN
is  ||| S:21202 E:21205 ||| VBZ
directed  ||| S:21205 E:21214 ||| VBN
to  ||| S:21214 E:21217 ||| TO
a  ||| S:21217 E:21219 ||| DT
method  ||| S:21219 E:21226 ||| NN
and  ||| S:21226 E:21230 ||| CC
diluent  ||| S:21230 E:21238 ||| NN
for  ||| S:21238 E:21242 ||| IN
stabilizing  ||| S:21242 E:21254 ||| VBG
biomolecules ||| S:21254 E:21266 ||| NN
,  ||| S:21266 E:21268 ||| ,
comprising  ||| S:21268 E:21279 ||| VBG
Tris  ||| S:21279 E:21284 ||| NNP
and  ||| S:21284 E:21288 ||| CC
a  ||| S:21288 E:21290 ||| DT
polyhydroxy  ||| S:21290 E:21302 ||| JJ
carbohydrate  ||| S:21302 E:21315 ||| NNS
selected  ||| S:21315 E:21324 ||| VBN
from  ||| S:21324 E:21329 ||| IN
the  ||| S:21329 E:21333 ||| DT
group  ||| S:21333 E:21339 ||| NN
consisting  ||| S:21339 E:21350 ||| VBG
of  ||| S:21350 E:21353 ||| IN
mannitol  ||| S:21353 E:21362 ||| NN
and  ||| S:21362 E:21366 ||| CC
trehalose ||| S:21366 E:21375 ||| NN
.  ||| S:21375 E:21377 ||| .
The  ||| S:21377 E:21381 ||| DT
diluent  ||| S:21381 E:21389 ||| NN
may  ||| S:21389 E:21393 ||| MD
optionally  ||| S:21393 E:21404 ||| RB
include  ||| S:21404 E:21412 ||| VBP
casein  ||| S:21412 E:21419 ||| VBN
added  ||| S:21419 E:21425 ||| VBN
as  ||| S:21425 E:21428 ||| IN
a  ||| S:21428 E:21430 ||| DT
background  ||| S:21430 E:21441 ||| NN
blocking  ||| S:21441 E:21450 ||| VBG
protein ||| S:21450 E:21457 ||| NN
.  ||| S:21457 E:21459 ||| .
The  ||| S:21459 E:21463 ||| DT
diluent  ||| S:21463 E:21471 ||| NN
may  ||| S:21471 E:21475 ||| MD
optionally  ||| S:21475 E:21486 ||| RB
include  ||| S:21486 E:21494 ||| VB
sodium  ||| S:21494 E:21501 ||| JJ
azide  ||| S:21501 E:21507 ||| NN
as  ||| S:21507 E:21510 ||| IN
an  ||| S:21510 E:21513 ||| DT
anti-microbial  ||| S:21513 E:21528 ||| JJ
agent ||| S:21528 E:21533 ||| NN
.  ||| S:21533 E:21535 ||| .
Mannitol  ||| S:21535 E:21544 ||| NNP
and ||| S:21544 E:21547 ||| CC
/ ||| S:21547 E:21548 ||| NNP
or  ||| S:21548 E:21551 ||| CC
trehalose  ||| S:21551 E:21561 ||| NNS
are  ||| S:21561 E:21565 ||| VBP
particularly  ||| S:21565 E:21578 ||| RB
useful  ||| S:21578 E:21585 ||| JJ
embodiments  ||| S:21585 E:21597 ||| NN
of  ||| S:21597 E:21600 ||| IN
polyhydroxy  ||| S:21600 E:21612 ||| JJ
carbohydrates ||| S:21612 E:21625 ||| NN
.  ||| S:21625 E:21648 ||| .
This  ||| S:21683 E:21688 ||| DT
application  ||| S:21688 E:21700 ||| NN
claims  ||| S:21700 E:21707 ||| NNS
priority  ||| S:21707 E:21716 ||| NN
to  ||| S:21716 E:21719 ||| TO
U.S.  ||| S:21719 E:21724 ||| NNP
Provisional  ||| S:21724 E:21736 ||| NNP
patent  ||| S:21736 E:21743 ||| NN
application  ||| S:21743 E:21755 ||| NN
Ser ||| S:21755 E:21758 ||| NNP
.  ||| S:21758 E:21760 ||| .
No.  ||| S:21760 E:21764 ||| NNP
60 ||| S:21764 E:21766 ||| CD
/ ||| S:21766 E:21767 ||| CD
696,026  ||| S:21767 E:21775 ||| CD
filed  ||| S:21775 E:21781 ||| VBD
06 ||| S:21781 E:21783 ||| CD
/ ||| S:21783 E:21784 ||| CD
30 ||| S:21784 E:21786 ||| CD
/ ||| S:21786 E:21787 ||| CD
2005 ||| S:21787 E:21791 ||| CD
,  ||| S:21791 E:21793 ||| ,
the  ||| S:21793 E:21797 ||| DT
entire  ||| S:21797 E:21804 ||| JJ
contents  ||| S:21804 E:21813 ||| NNS
of  ||| S:21813 E:21816 ||| IN
which  ||| S:21816 E:21822 ||| WDT
are  ||| S:21822 E:21826 ||| VBP
incorporated  ||| S:21826 E:21839 ||| VBN
by  ||| S:21839 E:21842 ||| IN
reference  ||| S:21842 E:21852 ||| NN
herein ||| S:21852 E:21858 ||| NN
.  ||| S:21858 E:21862 ||| .
The  ||| S:21903 E:21907 ||| DT
invention  ||| S:21907 E:21917 ||| NN
relates  ||| S:21917 E:21925 ||| VBZ
generally  ||| S:21925 E:21935 ||| RB
to  ||| S:21935 E:21938 ||| TO
the  ||| S:21938 E:21942 ||| DT
field  ||| S:21942 E:21948 ||| NN
of  ||| S:21948 E:21951 ||| IN
life  ||| S:21951 E:21956 ||| NN
sciences ||| S:21956 E:21964 ||| NNS
,  ||| S:21964 E:21966 ||| ,
more  ||| S:21966 E:21971 ||| RBR
particularly  ||| S:21971 E:21984 ||| RB
the  ||| S:21984 E:21988 ||| DT
field  ||| S:21988 E:21994 ||| NN
of  ||| S:21994 E:21997 ||| IN
preservation  ||| S:21997 E:22010 ||| NN
and  ||| S:22010 E:22014 ||| CC
storage  ||| S:22014 E:22022 ||| NN
of  ||| S:22022 E:22025 ||| IN
proteins ||| S:22025 E:22033 ||| NNS
,  ||| S:22033 E:22035 ||| ,
and  ||| S:22035 E:22039 ||| CC
further  ||| S:22039 E:22047 ||| JJ
to  ||| S:22047 E:22050 ||| TO
the  ||| S:22050 E:22054 ||| DT
field  ||| S:22054 E:22060 ||| NN
of  ||| S:22060 E:22063 ||| IN
stabilizing  ||| S:22063 E:22075 ||| VBG
biomolecules  ||| S:22075 E:22088 ||| NN
for  ||| S:22088 E:22092 ||| IN
subsequent  ||| S:22092 E:22103 ||| JJ
shipping  ||| S:22103 E:22112 ||| NN
and  ||| S:22112 E:22116 ||| CC
storage  ||| S:22116 E:22124 ||| NN
for  ||| S:22124 E:22128 ||| IN
later  ||| S:22128 E:22134 ||| JJ
use  ||| S:22134 E:22138 ||| NN
in  ||| S:22138 E:22141 ||| IN
Immunohistochemistry  ||| S:22141 E:22162 ||| NNP
(  ||| S:22162 E:22171 ||| -LRB-
IHC  ||| S:22171 E:22182 ||| NNP
) ||| S:22182 E:22183 ||| -RRB-
.  ||| S:22183 E:22187 ||| .
Buffered  ||| S:22219 E:22228 ||| JJ
protein  ||| S:22228 E:22236 ||| NN
solutions  ||| S:22236 E:22246 ||| NNS
have  ||| S:22246 E:22251 ||| VBP
long  ||| S:22251 E:22256 ||| RB
been  ||| S:22256 E:22261 ||| VBN
used  ||| S:22261 E:22266 ||| VBN
as  ||| S:22266 E:22269 ||| IN
diluents ||| S:22269 E:22277 ||| NN
,  ||| S:22277 E:22279 ||| ,
or  ||| S:22279 E:22282 ||| CC
stabilizing  ||| S:22282 E:22294 ||| VBG
buffered  ||| S:22294 E:22303 ||| JJ
solutions ||| S:22303 E:22312 ||| NNS
,  ||| S:22312 E:22314 ||| ,
for  ||| S:22314 E:22318 ||| IN
storage  ||| S:22318 E:22326 ||| NN
and  ||| S:22326 E:22330 ||| CC
dilution  ||| S:22330 E:22339 ||| NN
of  ||| S:22339 E:22342 ||| IN
active  ||| S:22342 E:22349 ||| JJ
biomolecules  ||| S:22349 E:22362 ||| JJ
such  ||| S:22362 E:22367 ||| JJ
as  ||| S:22367 E:22370 ||| IN
for  ||| S:22370 E:22374 ||| IN
example  ||| S:22374 E:22382 ||| NN
antibodies ||| S:22382 E:22392 ||| NNS
.  ||| S:22392 E:22394 ||| .
Diluents  ||| S:22394 E:22403 ||| NNP
also  ||| S:22403 E:22408 ||| RB
serve  ||| S:22408 E:22414 ||| VB
the  ||| S:22414 E:22418 ||| DT
function  ||| S:22418 E:22427 ||| NN
of  ||| S:22427 E:22430 ||| IN
reducing  ||| S:22430 E:22439 ||| VBG
non-specific  ||| S:22439 E:22452 ||| JJ
binding  ||| S:22452 E:22460 ||| NN
to  ||| S:22460 E:22463 ||| TO
containers  ||| S:22463 E:22474 ||| VB
they  ||| S:22474 E:22479 ||| PRP
are  ||| S:22479 E:22483 ||| VBP
in ||| S:22483 E:22485 ||| IN
,  ||| S:22485 E:22487 ||| ,
and  ||| S:22487 E:22491 ||| CC
to  ||| S:22491 E:22494 ||| TO
tissue  ||| S:22494 E:22501 ||| NN
components  ||| S:22501 E:22512 ||| NNS
they  ||| S:22512 E:22517 ||| PRP
may  ||| S:22517 E:22521 ||| MD
later  ||| S:22521 E:22527 ||| RB
contact  ||| S:22527 E:22535 ||| VB
in  ||| S:22535 E:22538 ||| IN
normal  ||| S:22538 E:22545 ||| JJ
analytical  ||| S:22545 E:22556 ||| JJ
use ||| S:22556 E:22559 ||| NN
.  ||| S:22559 E:22561 ||| .
Sugars  ||| S:22561 E:22568 ||| JJ
such  ||| S:22568 E:22573 ||| JJ
as  ||| S:22573 E:22576 ||| IN
Sorbitol  ||| S:22576 E:22585 ||| NNP
( ||| S:22585 E:22586 ||| -LRB-
Andersson ||| S:22586 E:22595 ||| NNP
,  ||| S:22595 E:22597 ||| ,
Maria ||| S:22597 E:22602 ||| NNP
,  ||| S:22602 E:22604 ||| ,
Protein  ||| S:22604 E:22612 ||| NNP
Stabilization ||| S:22612 E:22625 ||| NNP
.  ||| S:22625 E:22627 ||| .
Some  ||| S:22627 E:22632 ||| DT
Methods  ||| S:22632 E:22640 ||| NNP
and  ||| S:22640 E:22644 ||| CC
Mechanisms ||| S:22644 E:22654 ||| NNP
,  ||| S:22654 E:22656 ||| ,
Dissertation  ||| S:22656 E:22669 ||| NNP
abstract ||| S:22669 E:22677 ||| NN
,  ||| S:22677 E:22679 ||| ,
Lund  ||| S:22679 E:22684 ||| NNP
University ||| S:22684 E:22694 ||| NNP
,  ||| S:22694 E:22696 ||| ,
1999 ||| S:22696 E:22700 ||| CD
,  ||| S:22700 E:22702 ||| ,
http://theses.lub.lu.se/postgrad/ ||| S:22702 E:22735 ||| CD
)  ||| S:22735 E:22737 ||| -RRB-
have  ||| S:22737 E:22742 ||| VBP
been  ||| S:22742 E:22747 ||| VBN
used  ||| S:22747 E:22752 ||| VBN
historically  ||| S:22752 E:22765 ||| RB
to  ||| S:22765 E:22768 ||| TO
improve  ||| S:22768 E:22776 ||| VB
the  ||| S:22776 E:22780 ||| DT
stability  ||| S:22780 E:22790 ||| NN
of  ||| S:22790 E:22793 ||| IN
proteins  ||| S:22793 E:22802 ||| NNS
during  ||| S:22802 E:22809 ||| IN
and  ||| S:22809 E:22813 ||| CC
after  ||| S:22813 E:22819 ||| IN
the  ||| S:22819 E:22823 ||| DT
lyophilization  ||| S:22823 E:22838 ||| JJ
process  ||| S:22838 E:22846 ||| NN
( ||| S:22846 E:22847 ||| -LRB-
essentially  ||| S:22847 E:22859 ||| RB
freeze-drying ||| S:22859 E:22872 ||| JJ
)  ||| S:22872 E:22874 ||| -RRB-
to  ||| S:22874 E:22877 ||| TO
improve  ||| S:22877 E:22885 ||| VB
their  ||| S:22885 E:22891 ||| PRP$
shelf-life ||| S:22891 E:22901 ||| JJ
.  ||| S:22901 E:22903 ||| .
Lyophilized  ||| S:22903 E:22915 ||| JJ
antibodies  ||| S:22915 E:22926 ||| NNS
generally  ||| S:22926 E:22936 ||| RB
have  ||| S:22936 E:22941 ||| VBP
much  ||| S:22941 E:22946 ||| RB
longer  ||| S:22946 E:22953 ||| RBR
shelf-lives ||| S:22953 E:22964 ||| JJ
,  ||| S:22964 E:22966 ||| ,
and  ||| S:22966 E:22970 ||| CC
in  ||| S:22970 E:22973 ||| IN
some  ||| S:22973 E:22978 ||| DT
cases  ||| S:22978 E:22984 ||| NNS
may  ||| S:22984 E:22988 ||| MD
be  ||| S:22988 E:22991 ||| VB
stored  ||| S:22991 E:22998 ||| VBN
indefinitely  ||| S:22998 E:23011 ||| RB
if  ||| S:23011 E:23014 ||| IN
kept  ||| S:23014 E:23019 ||| VBN
in  ||| S:23019 E:23022 ||| IN
a  ||| S:23022 E:23024 ||| DT
low-temperature  ||| S:23024 E:23040 ||| JJ
environment ||| S:23040 E:23051 ||| NN
.  ||| S:23051 E:23053 ||| .
However ||| S:23053 E:23060 ||| RB
,  ||| S:23060 E:23062 ||| ,
antibodies  ||| S:23062 E:23073 ||| NNS
stored  ||| S:23073 E:23080 ||| VBD
in  ||| S:23080 E:23083 ||| IN
diluents  ||| S:23083 E:23092 ||| VBG
still  ||| S:23092 E:23098 ||| RB
do  ||| S:23098 E:23101 ||| VBP
not  ||| S:23101 E:23105 ||| RB
match  ||| S:23105 E:23111 ||| VB
the  ||| S:23111 E:23115 ||| DT
shelf  ||| S:23115 E:23121 ||| NN
life  ||| S:23121 E:23126 ||| NN
of  ||| S:23126 E:23129 ||| IN
a  ||| S:23129 E:23131 ||| DT
lyophilized  ||| S:23131 E:23143 ||| JJ
antibody ||| S:23143 E:23151 ||| NN
,  ||| S:23151 E:23153 ||| ,
so  ||| S:23153 E:23156 ||| RB
improved  ||| S:23156 E:23165 ||| JJ
diluents  ||| S:23165 E:23174 ||| NNS
are  ||| S:23174 E:23178 ||| VBP
still  ||| S:23178 E:23184 ||| RB
needed ||| S:23184 E:23190 ||| VBN
.  ||| S:23190 E:23194 ||| .
Numerous  ||| S:23194 E:23203 ||| JJ
publications  ||| S:23203 E:23216 ||| NNS
in  ||| S:23216 E:23219 ||| IN
the  ||| S:23219 E:23223 ||| DT
art  ||| S:23223 E:23227 ||| NN
disclose  ||| S:23227 E:23236 ||| NN
means  ||| S:23236 E:23242 ||| VBZ
of  ||| S:23242 E:23245 ||| IN
increasing  ||| S:23245 E:23256 ||| VBG
the  ||| S:23256 E:23260 ||| DT
stability  ||| S:23260 E:23270 ||| NN
of  ||| S:23270 E:23273 ||| IN
a  ||| S:23273 E:23275 ||| DT
lyophilized  ||| S:23275 E:23287 ||| JJ
reagent ||| S:23287 E:23294 ||| NN
,  ||| S:23294 E:23296 ||| ,
and  ||| S:23296 E:23300 ||| CC
the  ||| S:23300 E:23304 ||| DT
difficulties  ||| S:23304 E:23317 ||| NNS
inherent  ||| S:23317 E:23326 ||| VBP
even  ||| S:23326 E:23331 ||| RB
within  ||| S:23331 E:23338 ||| IN
this  ||| S:23338 E:23343 ||| DT
state-of-the-art  ||| S:23343 E:23360 ||| JJ
technology ||| S:23360 E:23370 ||| NN
.  ||| S:23370 E:23372 ||| .
For  ||| S:23372 E:23376 ||| IN
example ||| S:23376 E:23383 ||| NN
,  ||| S:23383 E:23385 ||| ,
U.S.  ||| S:23385 E:23390 ||| NNP
Pat ||| S:23390 E:23393 ||| NNP
.  ||| S:23393 E:23395 ||| .
Nos.  ||| S:23395 E:23400 ||| NNP
5,955,448 ||| S:23400 E:23409 ||| NNP
,  ||| S:23409 E:23411 ||| ,
4,496,537 ||| S:23411 E:23420 ||| NNP
,  ||| S:23420 E:23422 ||| ,
and  ||| S:23422 E:23426 ||| CC
PCT  ||| S:23426 E:23430 ||| NNP
filing  ||| S:23430 E:23437 ||| NN
WO  ||| S:23437 E:23440 ||| NNP
97 ||| S:23440 E:23442 ||| CD
/ ||| S:23442 E:23443 ||| CD
04801  ||| S:23443 E:23449 ||| CD
all  ||| S:23449 E:23453 ||| DT
disclose  ||| S:23453 E:23462 ||| JJ
improvements  ||| S:23462 E:23475 ||| NNS
in  ||| S:23475 E:23478 ||| IN
lyophilization  ||| S:23478 E:23493 ||| JJ
techniques ||| S:23493 E:23503 ||| NNS
.  ||| S:23503 E:23505 ||| .
Lyophilization  ||| S:23505 E:23520 ||| NNP
of  ||| S:23520 E:23523 ||| IN
protein-containing  ||| S:23523 E:23542 ||| JJ
solutions ||| S:23542 E:23551 ||| NNS
,  ||| S:23551 E:23553 ||| ,
however ||| S:23553 E:23560 ||| RB
,  ||| S:23560 E:23562 ||| ,
imposes  ||| S:23562 E:23570 ||| VBZ
major  ||| S:23570 E:23576 ||| JJ
costs  ||| S:23576 E:23582 ||| NNS
and  ||| S:23582 E:23586 ||| CC
inconvenience  ||| S:23586 E:23600 ||| NN
on  ||| S:23600 E:23603 ||| IN
the  ||| S:23603 E:23607 ||| DT
manufacturer  ||| S:23607 E:23620 ||| NN
and  ||| S:23620 E:23624 ||| CC
the  ||| S:23624 E:23628 ||| DT
end  ||| S:23628 E:23632 ||| NN
user ||| S:23632 E:23636 ||| NN
,  ||| S:23636 E:23638 ||| ,
as  ||| S:23638 E:23641 ||| RB
well  ||| S:23641 E:23646 ||| RB
as  ||| S:23646 E:23649 ||| IN
introducing  ||| S:23649 E:23661 ||| VBG
an  ||| S:23661 E:23664 ||| DT
increased  ||| S:23664 E:23674 ||| JJ
risk  ||| S:23674 E:23679 ||| NN
of  ||| S:23679 E:23682 ||| IN
reconstitution  ||| S:23682 E:23697 ||| JJ
errors  ||| S:23697 E:23704 ||| NNS
and  ||| S:23704 E:23708 ||| CC
contamination ||| S:23708 E:23721 ||| NN
.  ||| S:23721 E:23723 ||| .
Additionally ||| S:23723 E:23735 ||| RB
,  ||| S:23735 E:23737 ||| ,
freeze-drying  ||| S:23737 E:23751 ||| JJ
of  ||| S:23751 E:23754 ||| IN
a  ||| S:23754 E:23756 ||| DT
solution  ||| S:23756 E:23765 ||| NN
requires  ||| S:23765 E:23774 ||| VBZ
special  ||| S:23774 E:23782 ||| JJ
equipment  ||| S:23782 E:23792 ||| NN
and  ||| S:23792 E:23796 ||| CC
ultimately  ||| S:23796 E:23807 ||| RB
can  ||| S:23807 E:23811 ||| MD
lead  ||| S:23811 E:23816 ||| VB
to  ||| S:23816 E:23819 ||| TO
protein  ||| S:23819 E:23827 ||| VB
degradation  ||| S:23827 E:23839 ||| VBN
when  ||| S:23839 E:23844 ||| WRB
repeated  ||| S:23844 E:23853 ||| JJ
cycling  ||| S:23853 E:23861 ||| NN
occurs ||| S:23861 E:23867 ||| VBZ
.  ||| S:23867 E:23869 ||| .
For  ||| S:23869 E:23873 ||| IN
commercial  ||| S:23873 E:23884 ||| JJ
use ||| S:23884 E:23887 ||| NN
,  ||| S:23887 E:23889 ||| ,
deterioration  ||| S:23889 E:23903 ||| NN
of  ||| S:23903 E:23906 ||| IN
polypeptides  ||| S:23906 E:23919 ||| NN
and  ||| S:23919 E:23923 ||| CC
antigens  ||| S:23923 E:23932 ||| NN
in  ||| S:23932 E:23935 ||| IN
aqueous  ||| S:23935 E:23943 ||| JJ
solutions  ||| S:23943 E:23953 ||| NNS
is  ||| S:23953 E:23956 ||| VBZ
costly  ||| S:23956 E:23963 ||| JJ
because  ||| S:23963 E:23971 ||| IN
such  ||| S:23971 E:23976 ||| JJ
solutions  ||| S:23976 E:23986 ||| NNS
require  ||| S:23986 E:23994 ||| VBP
replacement  ||| S:23994 E:24006 ||| NN
after  ||| S:24006 E:24012 ||| IN
only  ||| S:24012 E:24017 ||| RB
a  ||| S:24017 E:24019 ||| DT
short  ||| S:24019 E:24025 ||| JJ
storage  ||| S:24025 E:24033 ||| NN
life ||| S:24033 E:24037 ||| NN
.  ||| S:24037 E:24041 ||| .
PCT  ||| S:24041 E:24045 ||| NNP
pub ||| S:24045 E:24048 ||| NN
.  ||| S:24048 E:24050 ||| .
No ||| S:24050 E:24052 ||| UH
.  ||| S:24052 E:24054 ||| .
WO99 ||| S:24054 E:24058 ||| CD
/ ||| S:24058 E:24059 ||| CD
15901  ||| S:24059 E:24065 ||| CD
discloses  ||| S:24065 E:24075 ||| VBZ
a  ||| S:24075 E:24077 ||| DT
diluent  ||| S:24077 E:24085 ||| NN
for  ||| S:24085 E:24089 ||| IN
the  ||| S:24089 E:24093 ||| DT
stabilization  ||| S:24093 E:24107 ||| NN
of  ||| S:24107 E:24110 ||| IN
antigens ||| S:24110 E:24118 ||| NN
,  ||| S:24118 E:24120 ||| ,
in  ||| S:24120 E:24123 ||| IN
particular ||| S:24123 E:24133 ||| JJ
,  ||| S:24133 E:24135 ||| ,
Hepatitis  ||| S:24135 E:24145 ||| NNP
C  ||| S:24145 E:24147 ||| NNP
Virus  ||| S:24147 E:24153 ||| NNP
( ||| S:24153 E:24154 ||| -LRB-
HCV ||| S:24154 E:24157 ||| NNP
)  ||| S:24157 E:24159 ||| -RRB-
antigens ||| S:24159 E:24167 ||| NN
.  ||| S:24167 E:24169 ||| .
The  ||| S:24169 E:24173 ||| DT
HCV  ||| S:24173 E:24177 ||| NNP
diluent  ||| S:24177 E:24185 ||| NN
comprises  ||| S:24185 E:24195 ||| VBZ
a  ||| S:24195 E:24197 ||| DT
reducing  ||| S:24197 E:24206 ||| VBG
agent  ||| S:24206 E:24212 ||| NN
to  ||| S:24212 E:24215 ||| TO
keep  ||| S:24215 E:24220 ||| VB
the  ||| S:24220 E:24224 ||| DT
HCV  ||| S:24224 E:24228 ||| NNP
antigens  ||| S:24228 E:24237 ||| NN
in  ||| S:24237 E:24240 ||| IN
a  ||| S:24240 E:24242 ||| DT
reduced  ||| S:24242 E:24250 ||| JJ
form ||| S:24250 E:24254 ||| NN
.  ||| S:24254 E:24256 ||| .
The  ||| S:24256 E:24260 ||| DT
publication  ||| S:24260 E:24272 ||| NN
reports  ||| S:24272 E:24280 ||| NNS
that  ||| S:24280 E:24285 ||| IN
the  ||| S:24285 E:24289 ||| DT
inclusion  ||| S:24289 E:24299 ||| NN
of  ||| S:24299 E:24302 ||| IN
a  ||| S:24302 E:24304 ||| DT
reducing  ||| S:24304 E:24313 ||| VBG
agent  ||| S:24313 E:24319 ||| NN
in  ||| S:24319 E:24322 ||| IN
a  ||| S:24322 E:24324 ||| DT
diluent  ||| S:24324 E:24332 ||| NN
maintained  ||| S:24332 E:24343 ||| VBD
the  ||| S:24343 E:24347 ||| DT
immunoreactivity  ||| S:24347 E:24364 ||| NN
of  ||| S:24364 E:24367 ||| IN
an  ||| S:24367 E:24370 ||| DT
HCV  ||| S:24370 E:24374 ||| NNP
antigen  ||| S:24374 E:24382 ||| NN
for  ||| S:24382 E:24386 ||| IN
up  ||| S:24386 E:24389 ||| RB
to  ||| S:24389 E:24392 ||| TO
seven  ||| S:24392 E:24398 ||| CD
days ||| S:24398 E:24402 ||| NNS
.  ||| S:24402 E:24404 ||| .
The  ||| S:24404 E:24408 ||| DT
reported  ||| S:24408 E:24417 ||| JJ
diluent  ||| S:24417 E:24425 ||| NN
further  ||| S:24425 E:24433 ||| RBR
comprises  ||| S:24433 E:24443 ||| JJ
sodium  ||| S:24443 E:24450 ||| JJ
phosphate ||| S:24450 E:24459 ||| NN
,  ||| S:24459 E:24461 ||| ,
pH  ||| S:24461 E:24464 ||| JJ
6.5  ||| S:24464 E:24468 ||| CD
( ||| S:24468 E:24469 ||| -LRB-
or  ||| S:24469 E:24472 ||| CC
other  ||| S:24472 E:24478 ||| JJ
buffer ||| S:24478 E:24484 ||| NN
) ||| S:24484 E:24485 ||| -RRB-
,  ||| S:24485 E:24487 ||| ,
EDTA  ||| S:24487 E:24492 ||| NNP
( ||| S:24492 E:24493 ||| -LRB-
or  ||| S:24493 E:24496 ||| CC
other  ||| S:24496 E:24502 ||| JJ
chelator ||| S:24502 E:24510 ||| NN
) ||| S:24510 E:24511 ||| -RRB-
,  ||| S:24511 E:24513 ||| ,
DTT  ||| S:24513 E:24517 ||| NNP
( ||| S:24517 E:24518 ||| -LRB-
or  ||| S:24518 E:24521 ||| CC
other  ||| S:24521 E:24527 ||| JJ
reducing  ||| S:24527 E:24536 ||| VBG
agent ||| S:24536 E:24541 ||| NN
) ||| S:24541 E:24542 ||| -RRB-
,  ||| S:24542 E:24544 ||| ,
gelatin  ||| S:24544 E:24552 ||| NNS
( ||| S:24552 E:24553 ||| -LRB-
or  ||| S:24553 E:24556 ||| CC
other  ||| S:24556 E:24562 ||| JJ
protein  ||| S:24562 E:24570 ||| NN
blocking  ||| S:24570 E:24579 ||| VBG
source ||| S:24579 E:24585 ||| NN
) ||| S:24585 E:24586 ||| -RRB-
,  ||| S:24586 E:24588 ||| ,
ammonium  ||| S:24588 E:24597 ||| FW
thiocyanate  ||| S:24597 E:24609 ||| FW
( ||| S:24609 E:24610 ||| -LRB-
or  ||| S:24610 E:24613 ||| CC
other  ||| S:24613 E:24619 ||| JJ
chaotrope ||| S:24619 E:24628 ||| NN
) ||| S:24628 E:24629 ||| -RRB-
,  ||| S:24629 E:24631 ||| ,
sodium  ||| S:24631 E:24638 ||| FW
azide  ||| S:24638 E:24644 ||| FW
( ||| S:24644 E:24645 ||| -LRB-
or  ||| S:24645 E:24648 ||| CC
other  ||| S:24648 E:24654 ||| JJ
preservative ||| S:24654 E:24666 ||| NN
)  ||| S:24666 E:24668 ||| -RRB-
and  ||| S:24668 E:24672 ||| CC
SDS  ||| S:24672 E:24676 ||| NNP
( ||| S:24676 E:24677 ||| -LRB-
or  ||| S:24677 E:24680 ||| CC
other  ||| S:24680 E:24686 ||| JJ
detergent ||| S:24686 E:24695 ||| NN
) ||| S:24695 E:24696 ||| -RRB-
.  ||| S:24696 E:24700 ||| .
U.S.  ||| S:24700 E:24705 ||| NNP
Pat ||| S:24705 E:24708 ||| NNP
.  ||| S:24708 E:24710 ||| .
No.  ||| S:24710 E:24714 ||| NNP
4,956,274  ||| S:24714 E:24724 ||| NNP
concerns  ||| S:24724 E:24733 ||| NNS
techniques  ||| S:24733 E:24744 ||| NNS
for  ||| S:24744 E:24748 ||| IN
stabilizing  ||| S:24748 E:24760 ||| VBG
peptide  ||| S:24760 E:24768 ||| JJ
fragments  ||| S:24768 E:24778 ||| NNS
from  ||| S:24778 E:24783 ||| IN
beta-galactosidase  ||| S:24783 E:24802 ||| JJ
for  ||| S:24802 E:24806 ||| IN
use  ||| S:24806 E:24810 ||| NN
in  ||| S:24810 E:24813 ||| IN
complementation  ||| S:24813 E:24829 ||| JJ
assays ||| S:24829 E:24835 ||| NN
.  ||| S:24835 E:24837 ||| .
The  ||| S:24837 E:24841 ||| DT
solution  ||| S:24841 E:24850 ||| NN
disclosed  ||| S:24850 E:24860 ||| VBN
in  ||| S:24860 E:24863 ||| IN
U.S.  ||| S:24863 E:24868 ||| NNP
Pat ||| S:24868 E:24871 ||| NNP
.  ||| S:24871 E:24873 ||| .
No.  ||| S:24873 E:24877 ||| NNP
4,956,274  ||| S:24877 E:24887 ||| NNP
contained  ||| S:24887 E:24897 ||| VBD
an  ||| S:24897 E:24900 ||| DT
ionic  ||| S:24900 E:24906 ||| JJ
surfactant  ||| S:24906 E:24917 ||| NN
or  ||| S:24917 E:24920 ||| CC
a  ||| S:24920 E:24922 ||| DT
surfactant  ||| S:24922 E:24933 ||| NN
derived  ||| S:24933 E:24941 ||| VBN
from  ||| S:24941 E:24946 ||| IN
a  ||| S:24946 E:24948 ||| DT
sugar  ||| S:24948 E:24954 ||| NN
residue  ||| S:24954 E:24962 ||| NN
to  ||| S:24962 E:24965 ||| TO
slow  ||| S:24965 E:24970 ||| VB
degradation  ||| S:24970 E:24982 ||| VBN
of  ||| S:24982 E:24985 ||| IN
beta-galactosidase  ||| S:24985 E:25004 ||| JJ
peptide  ||| S:25004 E:25012 ||| JJ
fragments ||| S:25012 E:25021 ||| NNS
.  ||| S:25021 E:25023 ||| .
However ||| S:25023 E:25030 ||| RB
,  ||| S:25030 E:25032 ||| ,
the  ||| S:25032 E:25036 ||| DT
surfactants  ||| S:25036 E:25048 ||| NN
also  ||| S:25048 E:25053 ||| RB
denatured  ||| S:25053 E:25063 ||| VB
the  ||| S:25063 E:25067 ||| DT
enzyme  ||| S:25067 E:25074 ||| JJ
fragments ||| S:25074 E:25083 ||| NNS
,  ||| S:25083 E:25085 ||| ,
and  ||| S:25085 E:25089 ||| CC
thus  ||| S:25089 E:25094 ||| RB
had  ||| S:25094 E:25098 ||| VBD
to  ||| S:25098 E:25101 ||| TO
be  ||| S:25101 E:25104 ||| VB
removed  ||| S:25104 E:25112 ||| VBN
or  ||| S:25112 E:25115 ||| CC
neutralized  ||| S:25115 E:25127 ||| JJ
to  ||| S:25127 E:25130 ||| TO
enable  ||| S:25130 E:25137 ||| VB
the  ||| S:25137 E:25141 ||| DT
enzymatic  ||| S:25141 E:25151 ||| JJ
fragments  ||| S:25151 E:25161 ||| NNS
to  ||| S:25161 E:25164 ||| TO
return  ||| S:25164 E:25171 ||| VB
to  ||| S:25171 E:25174 ||| TO
their  ||| S:25174 E:25180 ||| PRP$
correct  ||| S:25180 E:25188 ||| JJ
conformation  ||| S:25188 E:25201 ||| NN
and  ||| S:25201 E:25205 ||| CC
regain  ||| S:25205 E:25212 ||| VB
enzymatic  ||| S:25212 E:25222 ||| JJ
activity ||| S:25222 E:25230 ||| NN
,  ||| S:25230 E:25232 ||| ,
indicating  ||| S:25232 E:25243 ||| VBG
that  ||| S:25243 E:25248 ||| IN
the  ||| S:25248 E:25252 ||| DT
solution  ||| S:25252 E:25261 ||| NN
did  ||| S:25261 E:25265 ||| VBD
not  ||| S:25265 E:25269 ||| RB
stabilize  ||| S:25269 E:25279 ||| VB
the  ||| S:25279 E:25283 ||| DT
native  ||| S:25283 E:25290 ||| JJ
form  ||| S:25290 E:25295 ||| NN
of  ||| S:25295 E:25298 ||| IN
the  ||| S:25298 E:25302 ||| DT
protein ||| S:25302 E:25309 ||| NN
.  ||| S:25309 E:25311 ||| .
The  ||| S:25311 E:25315 ||| DT
surfactants  ||| S:25315 E:25327 ||| NNS
are  ||| S:25327 E:25331 ||| VBP
neutralized  ||| S:25331 E:25343 ||| VBN
just  ||| S:25343 E:25348 ||| RB
prior  ||| S:25348 E:25354 ||| RB
to  ||| S:25354 E:25357 ||| TO
the  ||| S:25357 E:25361 ||| DT
assay  ||| S:25361 E:25367 ||| NN
by  ||| S:25367 E:25370 ||| IN
using  ||| S:25370 E:25376 ||| VBG
cyclodextrin ||| S:25376 E:25388 ||| NNS
.  ||| S:25388 E:25390 ||| .
Alternatively ||| S:25390 E:25403 ||| RB
,  ||| S:25403 E:25405 ||| ,
the  ||| S:25405 E:25409 ||| DT
action  ||| S:25409 E:25416 ||| NN
of  ||| S:25416 E:25419 ||| IN
the  ||| S:25419 E:25423 ||| DT
surfactants  ||| S:25423 E:25435 ||| NN
was  ||| S:25435 E:25439 ||| VBD
masked  ||| S:25439 E:25446 ||| VBN
with  ||| S:25446 E:25451 ||| IN
a  ||| S:25451 E:25453 ||| DT
high  ||| S:25453 E:25458 ||| JJ
concentration  ||| S:25458 E:25472 ||| NN
of  ||| S:25472 E:25475 ||| IN
serum ||| S:25475 E:25480 ||| NN
.  ||| S:25480 E:25482 ||| .
Additional  ||| S:25482 E:25493 ||| JJ
components  ||| S:25493 E:25504 ||| NNS
of  ||| S:25504 E:25507 ||| IN
the  ||| S:25507 E:25511 ||| DT
disclosed  ||| S:25511 E:25521 ||| VBN
reagent  ||| S:25521 E:25529 ||| NNS
included  ||| S:25529 E:25538 ||| VBD
a  ||| S:25538 E:25540 ||| DT
chelating  ||| S:25540 E:25550 ||| JJ
agent ||| S:25550 E:25555 ||| NN
,  ||| S:25555 E:25557 ||| ,
buffer ||| S:25557 E:25563 ||| NN
,  ||| S:25563 E:25565 ||| ,
bacteriocide ||| S:25565 E:25577 ||| NN
,  ||| S:25577 E:25579 ||| ,
magnesium  ||| S:25579 E:25589 ||| NN
or  ||| S:25589 E:25592 ||| CC
other  ||| S:25592 E:25598 ||| JJ
ions ||| S:25598 E:25602 ||| NN
,  ||| S:25602 E:25604 ||| ,
reducing  ||| S:25604 E:25613 ||| VBG
agents ||| S:25613 E:25619 ||| NNS
,  ||| S:25619 E:25621 ||| ,
solubilizing  ||| S:25621 E:25634 ||| JJ
agents  ||| S:25634 E:25641 ||| NNS
such  ||| S:25641 E:25646 ||| JJ
as  ||| S:25646 E:25649 ||| IN
solvents  ||| S:25649 E:25658 ||| NNS
like  ||| S:25658 E:25663 ||| IN
ethylene  ||| S:25663 E:25672 ||| NN
glycol ||| S:25672 E:25678 ||| NN
,  ||| S:25678 E:25680 ||| ,
and  ||| S:25680 E:25684 ||| CC
nonionic  ||| S:25684 E:25693 ||| JJ
detergents ||| S:25693 E:25703 ||| NNS
.  ||| S:25703 E:25705 ||| .
As  ||| S:25705 E:25708 ||| IN
those  ||| S:25708 E:25714 ||| DT
in  ||| S:25714 E:25717 ||| IN
the  ||| S:25717 E:25721 ||| DT
art  ||| S:25721 E:25725 ||| NN
will  ||| S:25725 E:25730 ||| MD
appreciate  ||| S:25730 E:25741 ||| VB
denaturing  ||| S:25741 E:25752 ||| NNS
and  ||| S:25752 E:25756 ||| CC
renaturing  ||| S:25756 E:25767 ||| JJ
proteins  ||| S:25767 E:25776 ||| NNS
or  ||| S:25776 E:25779 ||| CC
enzyme  ||| S:25779 E:25786 ||| JJ
fragments  ||| S:25786 E:25796 ||| NNS
may  ||| S:25796 E:25800 ||| MD
damage  ||| S:25800 E:25807 ||| VB
some  ||| S:25807 E:25812 ||| DT
antigenic  ||| S:25812 E:25822 ||| JJ
epitopes  ||| S:25822 E:25831 ||| NN
and  ||| S:25831 E:25835 ||| CC
render  ||| S:25835 E:25842 ||| VBD
them  ||| S:25842 E:25847 ||| PRP
inactive ||| S:25847 E:25855 ||| VBD
.  ||| S:25855 E:25859 ||| .
An  ||| S:26778 E:26781 ||| DT
embodiment  ||| S:26781 E:26792 ||| NN
of  ||| S:26792 E:26795 ||| IN
the  ||| S:26795 E:26799 ||| DT
invention  ||| S:26799 E:26809 ||| NN
is  ||| S:26809 E:26812 ||| VBZ
directed  ||| S:26812 E:26821 ||| VBN
to  ||| S:26821 E:26824 ||| TO
a  ||| S:26824 E:26826 ||| DT
diluent  ||| S:26826 E:26834 ||| NN
for  ||| S:26834 E:26838 ||| IN
stabilizing  ||| S:26838 E:26850 ||| VBG
biomolecules ||| S:26850 E:26862 ||| NN
,  ||| S:26862 E:26864 ||| ,
comprising  ||| S:26864 E:26875 ||| VBG
Tris  ||| S:26875 E:26880 ||| NNP
and  ||| S:26880 E:26884 ||| CC
a  ||| S:26884 E:26886 ||| DT
polyhydroxy  ||| S:26886 E:26898 ||| JJ
carbohydrate  ||| S:26898 E:26911 ||| NNS
selected  ||| S:26911 E:26920 ||| VBN
from  ||| S:26920 E:26925 ||| IN
the  ||| S:26925 E:26929 ||| DT
group  ||| S:26929 E:26935 ||| NN
consisting  ||| S:26935 E:26946 ||| VBG
of  ||| S:26946 E:26949 ||| IN
mannitol  ||| S:26949 E:26958 ||| NN
and  ||| S:26958 E:26962 ||| CC
trehalose ||| S:26962 E:26971 ||| NN
.  ||| S:26971 E:26973 ||| .
The  ||| S:26973 E:26977 ||| DT
diluent  ||| S:26977 E:26985 ||| NN
may  ||| S:26985 E:26989 ||| MD
optionally  ||| S:26989 E:27000 ||| RB
include  ||| S:27000 E:27008 ||| VBP
casein  ||| S:27008 E:27015 ||| VBN
added  ||| S:27015 E:27021 ||| VBN
as  ||| S:27021 E:27024 ||| IN
a  ||| S:27024 E:27026 ||| DT
background  ||| S:27026 E:27037 ||| NN
blocking  ||| S:27037 E:27046 ||| VBG
protein ||| S:27046 E:27053 ||| NN
.  ||| S:27053 E:27055 ||| .
The  ||| S:27055 E:27059 ||| DT
diluent  ||| S:27059 E:27067 ||| NN
may  ||| S:27067 E:27071 ||| MD
optionally  ||| S:27071 E:27082 ||| RB
include  ||| S:27082 E:27090 ||| VB
sodium  ||| S:27090 E:27097 ||| JJ
azide  ||| S:27097 E:27103 ||| NN
as  ||| S:27103 E:27106 ||| IN
an  ||| S:27106 E:27109 ||| DT
anti-microbial  ||| S:27109 E:27124 ||| JJ
agent ||| S:27124 E:27129 ||| NN
.  ||| S:27129 E:27131 ||| .
Mannitol  ||| S:27131 E:27140 ||| NNP
and ||| S:27140 E:27143 ||| CC
/ ||| S:27143 E:27144 ||| NNP
or  ||| S:27144 E:27147 ||| CC
trehalose  ||| S:27147 E:27157 ||| NNS
are  ||| S:27157 E:27161 ||| VBP
particularly  ||| S:27161 E:27174 ||| RB
useful  ||| S:27174 E:27181 ||| JJ
embodiments  ||| S:27181 E:27193 ||| NN
of  ||| S:27193 E:27196 ||| IN
polyhydroxy  ||| S:27196 E:27208 ||| JJ
carbohydrates ||| S:27208 E:27221 ||| NN
.  ||| S:27221 E:27223 ||| .
Another  ||| S:27223 E:27231 ||| DT
embodiment  ||| S:27231 E:27242 ||| NN
of  ||| S:27242 E:27245 ||| IN
the  ||| S:27245 E:27249 ||| DT
invention  ||| S:27249 E:27259 ||| NN
is  ||| S:27259 E:27262 ||| VBZ
a  ||| S:27262 E:27264 ||| DT
method  ||| S:27264 E:27271 ||| NN
for  ||| S:27271 E:27275 ||| IN
stabilizing  ||| S:27275 E:27287 ||| VBG
biomolecules  ||| S:27287 E:27300 ||| NNS
comprising  ||| S:27300 E:27311 ||| VBP
storing  ||| S:27311 E:27319 ||| VBG
a  ||| S:27319 E:27321 ||| DT
biomolecule  ||| S:27321 E:27333 ||| NN
in  ||| S:27333 E:27336 ||| IN
a  ||| S:27336 E:27338 ||| DT
diluent  ||| S:27338 E:27346 ||| NN
comprising  ||| S:27346 E:27357 ||| VBG
Tris  ||| S:27357 E:27362 ||| NNP
and  ||| S:27362 E:27366 ||| CC
a  ||| S:27366 E:27368 ||| DT
polyhydroxy  ||| S:27368 E:27380 ||| JJ
carbohydrate  ||| S:27380 E:27393 ||| NNS
selected  ||| S:27393 E:27402 ||| VBN
from  ||| S:27402 E:27407 ||| IN
the  ||| S:27407 E:27411 ||| DT
group  ||| S:27411 E:27417 ||| NN
consisting  ||| S:27417 E:27428 ||| VBG
of  ||| S:27428 E:27431 ||| IN
mannitol  ||| S:27431 E:27440 ||| NN
and  ||| S:27440 E:27444 ||| CC
trehalose ||| S:27444 E:27453 ||| NN
.  ||| S:27453 E:27457 ||| .
The  ||| S:28784 E:28788 ||| DT
diluent  ||| S:28788 E:28796 ||| NN
of  ||| S:28796 E:28799 ||| IN
the  ||| S:28799 E:28803 ||| DT
present  ||| S:28803 E:28811 ||| JJ
invention  ||| S:28811 E:28821 ||| NN
comprises  ||| S:28821 E:28831 ||| VBZ
a  ||| S:28831 E:28833 ||| DT
Tris  ||| S:28833 E:28838 ||| JJ
buffer ||| S:28838 E:28844 ||| NN
,  ||| S:28844 E:28846 ||| ,
and  ||| S:28846 E:28850 ||| CC
a  ||| S:28850 E:28852 ||| DT
polyhydroxy  ||| S:28852 E:28864 ||| JJ
carbohydrate  ||| S:28864 E:28877 ||| NNS
selected  ||| S:28877 E:28886 ||| VBN
from  ||| S:28886 E:28891 ||| IN
the  ||| S:28891 E:28895 ||| DT
group  ||| S:28895 E:28901 ||| NN
consisting  ||| S:28901 E:28912 ||| VBG
of  ||| S:28912 E:28915 ||| IN
Mannitol  ||| S:28915 E:28924 ||| NNP
and  ||| S:28924 E:28928 ||| CC
trehalose ||| S:28928 E:28937 ||| NN
.  ||| S:28937 E:28939 ||| .
Casein  ||| S:28939 E:28946 ||| NNP
may  ||| S:28946 E:28950 ||| MD
be  ||| S:28950 E:28953 ||| VB
useful  ||| S:28953 E:28960 ||| JJ
as  ||| S:28960 E:28963 ||| IN
a  ||| S:28963 E:28965 ||| DT
background  ||| S:28965 E:28976 ||| NN
blocker  ||| S:28976 E:28984 ||| NN
for  ||| S:28984 E:28988 ||| IN
subsequent  ||| S:28988 E:28999 ||| JJ
staining  ||| S:28999 E:29008 ||| NN
runs ||| S:29008 E:29012 ||| VBZ
.  ||| S:29012 E:29014 ||| .
Optionally ||| S:29014 E:29024 ||| NNP
,  ||| S:29024 E:29026 ||| ,
a  ||| S:29026 E:29028 ||| DT
preservative  ||| S:29028 E:29041 ||| JJ
anti-microbial  ||| S:29041 E:29056 ||| JJ
such  ||| S:29056 E:29061 ||| JJ
as  ||| S:29061 E:29064 ||| IN
sodium  ||| S:29064 E:29071 ||| JJ
azide  ||| S:29071 E:29077 ||| NN
may  ||| S:29077 E:29081 ||| MD
be  ||| S:29081 E:29084 ||| VB
used ||| S:29084 E:29088 ||| VBN
.  ||| S:29088 E:29090 ||| .
The  ||| S:29090 E:29094 ||| DT
preferred  ||| S:29094 E:29104 ||| JJ
diluent  ||| S:29104 E:29112 ||| NN
is  ||| S:29112 E:29115 ||| VBZ
Tris  ||| S:29115 E:29120 ||| NNP
( ||| S:29120 E:29121 ||| -LRB-
pH  ||| S:29121 E:29124 ||| NNP
7.2 ||| S:29124 E:29127 ||| CD
) ||| S:29127 E:29128 ||| -RRB-
,  ||| S:29128 E:29130 ||| ,
mannitol ||| S:29130 E:29138 ||| NN
,  ||| S:29138 E:29140 ||| ,
hydrolyzed  ||| S:29140 E:29151 ||| JJ
casein  ||| S:29151 E:29158 ||| NN
and  ||| S:29158 E:29162 ||| CC
sodium  ||| S:29162 E:29169 ||| JJ
azide ||| S:29169 E:29174 ||| NN
.  ||| S:29174 E:29176 ||| .
The  ||| S:29176 E:29180 ||| DT
diluent  ||| S:29180 E:29188 ||| NN
may  ||| S:29188 E:29192 ||| MD
be  ||| S:29192 E:29195 ||| VB
used  ||| S:29195 E:29200 ||| VBN
to  ||| S:29200 E:29203 ||| TO
dilute  ||| S:29203 E:29210 ||| VB
antibodies  ||| S:29210 E:29221 ||| NNS
or  ||| S:29221 E:29224 ||| CC
other  ||| S:29224 E:29230 ||| JJ
biomolecules  ||| S:29230 E:29243 ||| NN
for  ||| S:29243 E:29247 ||| IN
shipment  ||| S:29247 E:29256 ||| NN
and ||| S:29256 E:29259 ||| CC
/ ||| S:29259 E:29260 ||| NNP
or  ||| S:29260 E:29263 ||| CC
storage ||| S:29263 E:29270 ||| NN
.  ||| S:29270 E:29274 ||| .
A  ||| S:29700 E:29702 ||| DT
polyhydroxy  ||| S:29702 E:29714 ||| JJ
carbohydrate  ||| S:29714 E:29727 ||| NN
is  ||| S:29727 E:29730 ||| VBZ
an  ||| S:29730 E:29733 ||| DT
organic  ||| S:29733 E:29741 ||| JJ
compound  ||| S:29741 E:29750 ||| NN
consisting  ||| S:29750 E:29761 ||| VBG
of  ||| S:29761 E:29764 ||| IN
a  ||| S:29764 E:29766 ||| DT
chain  ||| S:29766 E:29772 ||| NN
of  ||| S:29772 E:29775 ||| IN
carbon  ||| S:29775 E:29782 ||| NN
atoms  ||| S:29782 E:29788 ||| NNS
to  ||| S:29788 E:29791 ||| TO
which  ||| S:29791 E:29797 ||| WDT
hydrogen  ||| S:29797 E:29806 ||| NN
and  ||| S:29806 E:29810 ||| CC
oxygen  ||| S:29810 E:29817 ||| NNS
are  ||| S:29817 E:29821 ||| VBP
attached  ||| S:29821 E:29830 ||| VBN
in  ||| S:29830 E:29833 ||| IN
a  ||| S:29833 E:29835 ||| DT
2 ||| S:29835 E:29836 ||| CD
: ||| S:29836 E:29837 ||| :
1  ||| S:29837 E:29839 ||| CD
ratio ||| S:29839 E:29844 ||| NN
,  ||| S:29844 E:29846 ||| ,
eg ||| S:29846 E:29848 ||| NN
,  ||| S:29848 E:29850 ||| ,
sugars ||| S:29850 E:29856 ||| NN
,  ||| S:29856 E:29858 ||| ,
starch ||| S:29858 E:29864 ||| NN
,  ||| S:29864 E:29866 ||| ,
glycogen ||| S:29866 E:29874 ||| NN
,  ||| S:29874 E:29876 ||| ,
cellulose ||| S:29876 E:29885 ||| NN
,  ||| S:29885 E:29887 ||| ,
and  ||| S:29887 E:29891 ||| CC
that  ||| S:29891 E:29896 ||| WDT
contain  ||| S:29896 E:29904 ||| VBP
multiple  ||| S:29904 E:29913 ||| JJ
hydroxy  ||| S:29913 E:29921 ||| NNS
(  ||| S:29921 E:29930 ||| -LRB-
OH ||| S:29930 E:29932 ||| NNP
)  ||| S:29932 E:29934 ||| -RRB-
groups ||| S:29934 E:29940 ||| NNS
.  ||| S:29940 E:29944 ||| .
An  ||| S:30418 E:30421 ||| DT
anti-microbial  ||| S:30421 E:30436 ||| JJ
agent  ||| S:30436 E:30442 ||| NN
is  ||| S:30442 E:30445 ||| VBZ
optionally  ||| S:30445 E:30456 ||| VBN
included ||| S:30456 E:30464 ||| VBN
.  ||| S:30464 E:30466 ||| .
One  ||| S:30466 E:30470 ||| CD
which  ||| S:30470 E:30476 ||| WDT
has  ||| S:30476 E:30480 ||| VBZ
been  ||| S:30480 E:30485 ||| VBN
found  ||| S:30485 E:30491 ||| VBN
to  ||| S:30491 E:30494 ||| TO
not  ||| S:30494 E:30498 ||| RB
interfere  ||| S:30498 E:30508 ||| VB
with  ||| S:30508 E:30513 ||| IN
IHC  ||| S:30513 E:30517 ||| NNP
requirements  ||| S:30517 E:30530 ||| NNS
is  ||| S:30530 E:30533 ||| VBZ
sodium  ||| S:30533 E:30540 ||| JJ
azide ||| S:30540 E:30545 ||| NN
.  ||| S:30545 E:30547 ||| .
It  ||| S:30547 E:30550 ||| PRP
is  ||| S:30550 E:30553 ||| VBZ
available  ||| S:30553 E:30563 ||| JJ
from  ||| S:30563 E:30568 ||| IN
many  ||| S:30568 E:30573 ||| JJ
suppliers ||| S:30573 E:30582 ||| NNS
,  ||| S:30582 E:30584 ||| ,
including  ||| S:30584 E:30594 ||| VBG
Sigma ||| S:30594 E:30599 ||| NNP
,  ||| S:30599 E:30601 ||| ,
P ||| S:30601 E:30602 ||| NNP
/ ||| S:30602 E:30603 ||| NNP
N  ||| S:30603 E:30605 ||| NNP
S-2002 ||| S:30605 E:30611 ||| NNP
.  ||| S:30611 E:30613 ||| .
The  ||| S:30613 E:30617 ||| DT
least  ||| S:30617 E:30623 ||| JJS
amount  ||| S:30623 E:30630 ||| NN
appropriate  ||| S:30630 E:30642 ||| JJ
to  ||| S:30642 E:30645 ||| TO
retard  ||| S:30645 E:30652 ||| VB
microbial  ||| S:30652 E:30662 ||| JJ
growth  ||| S:30662 E:30669 ||| NN
was  ||| S:30669 E:30673 ||| VBD
used  ||| S:30673 E:30678 ||| VBN
since  ||| S:30678 E:30684 ||| IN
it  ||| S:30684 E:30687 ||| PRP
is  ||| S:30687 E:30690 ||| VBZ
generally  ||| S:30690 E:30700 ||| RB
toxic ||| S:30700 E:30705 ||| JJ
,  ||| S:30705 E:30707 ||| ,
and  ||| S:30707 E:30711 ||| CC
can  ||| S:30711 E:30715 ||| MD
be  ||| S:30715 E:30718 ||| VB
explosive  ||| S:30718 E:30728 ||| JJ
under  ||| S:30728 E:30734 ||| IN
certain  ||| S:30734 E:30742 ||| JJ
circumstances.  ||| S:30742 E:30757 ||| CD
0.05  ||| S:30757 E:30762 ||| CD
wt. ||| S:30762 E:30765 ||| CD
/ ||| S:30765 E:30766 ||| CD
vol.  ||| S:30766 E:30771 ||| CD
%  ||| S:30771 E:30773 ||| NN
0.1 ||| S:30773 E:30776 ||| CD
%  ||| S:30776 E:30778 ||| NN
is  ||| S:30778 E:30781 ||| VBZ
a  ||| S:30781 E:30783 ||| DT
generally  ||| S:30783 E:30793 ||| RB
preferred  ||| S:30793 E:30803 ||| JJ
range ||| S:30803 E:30808 ||| NN
,  ||| S:30808 E:30810 ||| ,
and  ||| S:30810 E:30814 ||| CC
0.08 ||| S:30814 E:30818 ||| CD
%  ||| S:30818 E:30820 ||| NN
is  ||| S:30820 E:30823 ||| VBZ
a  ||| S:30823 E:30825 ||| DT
preferred  ||| S:30825 E:30835 ||| JJ
concentration  ||| S:30835 E:30849 ||| NN
used  ||| S:30849 E:30854 ||| VBN
herein ||| S:30854 E:30860 ||| NN
.  ||| S:30860 E:30864 ||| .
A  ||| S:30864 E:30866 ||| DT
background  ||| S:30866 E:30877 ||| NN
blocking  ||| S:30877 E:30886 ||| VBG
agent  ||| S:30886 E:30892 ||| NN
is  ||| S:30892 E:30895 ||| VBZ
generally  ||| S:30895 E:30905 ||| RB
used  ||| S:30905 E:30910 ||| VBN
with  ||| S:30910 E:30915 ||| IN
antibody  ||| S:30915 E:30924 ||| NN
diluents  ||| S:30924 E:30933 ||| VBZ
so  ||| S:30933 E:30936 ||| RB
that  ||| S:30936 E:30941 ||| IN
non-specific  ||| S:30941 E:30954 ||| JJ
protein-protein  ||| S:30954 E:30970 ||| JJ
binding  ||| S:30970 E:30978 ||| NN
is  ||| S:30978 E:30981 ||| VBZ
minimized  ||| S:30981 E:30991 ||| VBN
in  ||| S:30991 E:30994 ||| IN
subsequent  ||| S:30994 E:31005 ||| JJ
staining  ||| S:31005 E:31014 ||| NN
runs ||| S:31014 E:31018 ||| VBZ
.  ||| S:31018 E:31020 ||| .
Non-specific  ||| S:31020 E:31033 ||| JJ
protein-protein  ||| S:31033 E:31049 ||| JJ
binding  ||| S:31049 E:31057 ||| NN
may  ||| S:31057 E:31061 ||| MD
occur  ||| S:31061 E:31067 ||| VB
between  ||| S:31067 E:31075 ||| IN
the  ||| S:31075 E:31079 ||| DT
primary  ||| S:31079 E:31087 ||| JJ
antibody  ||| S:31087 E:31096 ||| NN
and  ||| S:31096 E:31100 ||| CC
many  ||| S:31100 E:31105 ||| JJ
other  ||| S:31105 E:31111 ||| JJ
proteins  ||| S:31111 E:31120 ||| NNS
in  ||| S:31120 E:31123 ||| IN
the  ||| S:31123 E:31127 ||| DT
tissue  ||| S:31127 E:31134 ||| NN
sample ||| S:31134 E:31140 ||| NN
,  ||| S:31140 E:31142 ||| ,
so  ||| S:31142 E:31145 ||| RB
some  ||| S:31145 E:31150 ||| DT
method  ||| S:31150 E:31157 ||| NN
of  ||| S:31157 E:31160 ||| IN
quenching  ||| S:31160 E:31170 ||| VBG
this  ||| S:31170 E:31183 ||| DT
stickiness  ||| S:31183 E:31202 ||| NN
should  ||| S:31202 E:31209 ||| MD
be  ||| S:31209 E:31212 ||| VB
used  ||| S:31212 E:31217 ||| VBN
to  ||| S:31217 E:31220 ||| TO
inhibit  ||| S:31220 E:31228 ||| VB
background  ||| S:31228 E:31239 ||| NN
signal ||| S:31239 E:31245 ||| NN
.  ||| S:31245 E:31247 ||| .
Many  ||| S:31247 E:31252 ||| JJ
proteins  ||| S:31252 E:31261 ||| NNS
can  ||| S:31261 E:31265 ||| MD
be  ||| S:31265 E:31268 ||| VB
used  ||| S:31268 E:31273 ||| VBN
for  ||| S:31273 E:31277 ||| IN
this ||| S:31277 E:31281 ||| DT
,  ||| S:31281 E:31283 ||| ,
including  ||| S:31283 E:31293 ||| VBG
Bovine  ||| S:31293 E:31300 ||| NNP
Serum  ||| S:31300 E:31306 ||| NNP
Albumin  ||| S:31306 E:31314 ||| NNP
( ||| S:31314 E:31315 ||| -LRB-
BSA ||| S:31315 E:31318 ||| NNP
) ||| S:31318 E:31319 ||| -RRB-
,  ||| S:31319 E:31321 ||| ,
Bovine  ||| S:31321 E:31328 ||| NNP
Gamma  ||| S:31328 E:31334 ||| NNP
Globulin  ||| S:31334 E:31343 ||| NNP
( ||| S:31343 E:31344 ||| -LRB-
BGG ||| S:31344 E:31347 ||| NNP
)  ||| S:31347 E:31349 ||| -RRB-
and  ||| S:31349 E:31353 ||| CC
hydrolyzed  ||| S:31353 E:31364 ||| JJ
casein ||| S:31364 E:31370 ||| NN
.  ||| S:31370 E:31372 ||| .
Particularly  ||| S:31372 E:31385 ||| RB
preferred  ||| S:31385 E:31395 ||| VBN
is  ||| S:31395 E:31398 ||| VBZ
hydrolyzed  ||| S:31398 E:31409 ||| JJ
casein  ||| S:31409 E:31416 ||| NN
from  ||| S:31416 E:31421 ||| IN
American  ||| S:31421 E:31430 ||| NNP
Casein  ||| S:31430 E:31437 ||| NNP
Co ||| S:31437 E:31439 ||| NNP
.  ||| S:31439 E:31441 ||| .
( ||| S:31441 E:31442 ||| -LRB-
Burlington ||| S:31442 E:31452 ||| NNP
,  ||| S:31452 E:31454 ||| ,
N.J. ||| S:31454 E:31458 ||| NNP
) ||| S:31458 E:31459 ||| -RRB-
,  ||| S:31459 E:31461 ||| ,
P ||| S:31461 E:31462 ||| NNP
/ ||| S:31462 E:31463 ||| NNP
N  ||| S:31463 E:31465 ||| NNP
HCA-411 ||| S:31465 E:31472 ||| NNP
.  ||| S:31472 E:31474 ||| .
Concentrations  ||| S:31474 E:31489 ||| NNS
of  ||| S:31489 E:31492 ||| IN
from  ||| S:31492 E:31497 ||| IN
2  ||| S:31497 E:31499 ||| CD
mg ||| S:31499 E:31501 ||| CD
/ ||| S:31501 E:31502 ||| CD
ml  ||| S:31502 E:31505 ||| NN
to  ||| S:31505 E:31508 ||| TO
15  ||| S:31508 E:31511 ||| CD
mg ||| S:31511 E:31513 ||| CD
/ ||| S:31513 E:31514 ||| CD
ml  ||| S:31514 E:31517 ||| NNS
are  ||| S:31517 E:31521 ||| VBP
useful ||| S:31521 E:31527 ||| JJ
,  ||| S:31527 E:31529 ||| ,
although  ||| S:31529 E:31538 ||| IN
2  ||| S:31538 E:31540 ||| CD
mg ||| S:31540 E:31542 ||| CD
/ ||| S:31542 E:31543 ||| CD
ml  ||| S:31543 E:31546 ||| NN
is  ||| S:31546 E:31549 ||| VBZ
preferred ||| S:31549 E:31558 ||| VBN
.  ||| S:31558 E:31560 ||| .
One  ||| S:31560 E:31564 ||| CD
of  ||| S:31564 E:31567 ||| IN
ordinary  ||| S:31567 E:31576 ||| JJ
skill  ||| S:31576 E:31582 ||| NN
in  ||| S:31582 E:31585 ||| IN
the  ||| S:31585 E:31589 ||| DT
histology  ||| S:31589 E:31599 ||| JJ
art  ||| S:31599 E:31603 ||| NN
will  ||| S:31603 E:31608 ||| MD
know  ||| S:31608 E:31613 ||| VB
of  ||| S:31613 E:31616 ||| IN
many  ||| S:31616 E:31621 ||| JJ
interchangeable  ||| S:31621 E:31637 ||| NNS
blocking  ||| S:31637 E:31646 ||| VBG
proteins  ||| S:31646 E:31655 ||| NNS
that  ||| S:31655 E:31660 ||| WDT
can  ||| S:31660 E:31664 ||| MD
be  ||| S:31664 E:31667 ||| VB
utilized ||| S:31667 E:31675 ||| NNS
.  ||| S:31675 E:31677 ||| .
Individual  ||| S:31677 E:31688 ||| JJ
blocking  ||| S:31688 E:31697 ||| VBG
buffers  ||| S:31697 E:31705 ||| NNS
are  ||| S:31705 E:31709 ||| VBP
not  ||| S:31709 E:31713 ||| RB
compatible  ||| S:31713 E:31724 ||| JJ
with  ||| S:31724 E:31729 ||| IN
every  ||| S:31729 E:31735 ||| DT
system ||| S:31735 E:31741 ||| NN
.  ||| S:31741 E:31743 ||| .
For  ||| S:31743 E:31747 ||| IN
this  ||| S:31747 E:31752 ||| DT
reason ||| S:31752 E:31758 ||| NN
,  ||| S:31758 E:31760 ||| ,
a  ||| S:31760 E:31762 ||| DT
variety  ||| S:31762 E:31770 ||| NN
of  ||| S:31770 E:31773 ||| IN
blockers  ||| S:31773 E:31782 ||| NN
in  ||| S:31782 E:31785 ||| IN
both  ||| S:31785 E:31790 ||| DT
Tris  ||| S:31790 E:31795 ||| NNP
buffered  ||| S:31795 E:31804 ||| FW
saline  ||| S:31804 E:31811 ||| FW
( ||| S:31811 E:31812 ||| -LRB-
TBS ||| S:31812 E:31815 ||| NNP
)  ||| S:31815 E:31817 ||| -RRB-
and  ||| S:31817 E:31821 ||| CC
phosphate  ||| S:31821 E:31831 ||| FW
buffered  ||| S:31831 E:31840 ||| FW
saline  ||| S:31840 E:31847 ||| FW
( ||| S:31847 E:31848 ||| -LRB-
PBS ||| S:31848 E:31851 ||| NNP
)  ||| S:31851 E:31853 ||| -RRB-
are  ||| S:31853 E:31857 ||| VBP
available ||| S:31857 E:31866 ||| JJ
.  ||| S:31866 E:31868 ||| .
The  ||| S:31868 E:31872 ||| DT
proper  ||| S:31872 E:31879 ||| JJ
choice  ||| S:31879 E:31886 ||| NN
of  ||| S:31886 E:31889 ||| IN
blocker  ||| S:31889 E:31897 ||| NN
for  ||| S:31897 E:31901 ||| IN
a  ||| S:31901 E:31903 ||| DT
given  ||| S:31903 E:31909 ||| VBN
tissue  ||| S:31909 E:31916 ||| NN
depends  ||| S:31916 E:31924 ||| VBZ
on  ||| S:31924 E:31927 ||| IN
the  ||| S:31927 E:31931 ||| DT
antigen  ||| S:31931 E:31939 ||| NN
itself  ||| S:31939 E:31946 ||| PRP
and  ||| S:31946 E:31950 ||| CC
on  ||| S:31950 E:31953 ||| IN
the  ||| S:31953 E:31957 ||| DT
type  ||| S:31957 E:31962 ||| NN
of  ||| S:31962 E:31965 ||| IN
enzyme  ||| S:31965 E:31972 ||| JJ
conjugate  ||| S:31972 E:31982 ||| NN
to  ||| S:31982 E:31985 ||| TO
be  ||| S:31985 E:31988 ||| VB
used ||| S:31988 E:31992 ||| VBN
.  ||| S:31992 E:31994 ||| .
For  ||| S:31994 E:31998 ||| IN
example ||| S:31998 E:32005 ||| NN
,  ||| S:32005 E:32007 ||| ,
with  ||| S:32007 E:32012 ||| IN
applications  ||| S:32012 E:32025 ||| NNS
using  ||| S:32025 E:32031 ||| VBG
an  ||| S:32031 E:32034 ||| DT
alkaline  ||| S:32034 E:32043 ||| JJ
phosphatase  ||| S:32043 E:32055 ||| JJ
conjugate ||| S:32055 E:32064 ||| NN
,  ||| S:32064 E:32066 ||| ,
a  ||| S:32066 E:32068 ||| DT
blocking  ||| S:32068 E:32077 ||| JJ
buffer  ||| S:32077 E:32084 ||| NN
in  ||| S:32084 E:32087 ||| IN
TBS  ||| S:32087 E:32091 ||| NNP
should  ||| S:32091 E:32098 ||| MD
be  ||| S:32098 E:32101 ||| VB
selected ||| S:32101 E:32109 ||| VBN
,  ||| S:32109 E:32111 ||| ,
because  ||| S:32111 E:32119 ||| IN
PBS  ||| S:32119 E:32123 ||| NNP
interferes  ||| S:32123 E:32134 ||| VBZ
with  ||| S:32134 E:32139 ||| IN
alkaline  ||| S:32139 E:32148 ||| JJ
phosphatase ||| S:32148 E:32159 ||| NN
.  ||| S:32159 E:32161 ||| .
The  ||| S:32161 E:32165 ||| DT
ideal  ||| S:32165 E:32171 ||| NN
blocking  ||| S:32171 E:32180 ||| VBG
buffer  ||| S:32180 E:32187 ||| NN
will  ||| S:32187 E:32192 ||| MD
bind  ||| S:32192 E:32197 ||| VB
to  ||| S:32197 E:32200 ||| TO
all  ||| S:32200 E:32204 ||| DT
potential  ||| S:32204 E:32214 ||| JJ
sites  ||| S:32214 E:32220 ||| NNS
of  ||| S:32220 E:32223 ||| IN
nonspecific  ||| S:32223 E:32235 ||| JJ
interaction ||| S:32235 E:32246 ||| NN
,  ||| S:32246 E:32248 ||| ,
eliminating  ||| S:32248 E:32260 ||| VBG
background  ||| S:32260 E:32271 ||| NN
altogether  ||| S:32271 E:32282 ||| RB
without  ||| S:32282 E:32290 ||| IN
altering  ||| S:32290 E:32299 ||| VBG
or  ||| S:32299 E:32302 ||| CC
obscuring  ||| S:32302 E:32312 ||| VBG
the  ||| S:32312 E:32316 ||| DT
epitope  ||| S:32316 E:32324 ||| NN
for  ||| S:32324 E:32328 ||| IN
antibody  ||| S:32328 E:32337 ||| NN
binding ||| S:32337 E:32344 ||| NN
.  ||| S:32344 E:32346 ||| .
For  ||| S:32346 E:32350 ||| IN
true  ||| S:32350 E:32355 ||| JJ
optimization  ||| S:32355 E:32368 ||| NN
of  ||| S:32368 E:32371 ||| IN
the  ||| S:32371 E:32375 ||| DT
blocking  ||| S:32375 E:32384 ||| JJ
step  ||| S:32384 E:32389 ||| NN
for  ||| S:32389 E:32393 ||| IN
a  ||| S:32393 E:32395 ||| DT
particular  ||| S:32395 E:32406 ||| JJ
immunohistochemical  ||| S:32406 E:32426 ||| JJ
assay ||| S:32426 E:32431 ||| NN
,  ||| S:32431 E:32433 ||| ,
empirical  ||| S:32433 E:32443 ||| JJ
testing  ||| S:32443 E:32451 ||| NN
is  ||| S:32451 E:32454 ||| VBZ
essential ||| S:32454 E:32463 ||| JJ
.  ||| S:32463 E:32465 ||| .
Many  ||| S:32465 E:32470 ||| JJ
factors ||| S:32470 E:32477 ||| NNS
,  ||| S:32477 E:32479 ||| ,
including  ||| S:32479 E:32489 ||| VBG
various  ||| S:32489 E:32497 ||| JJ
protein ||| S:32497 E:32504 ||| NN
: ||| S:32504 E:32505 ||| :
protein  ||| S:32505 E:32513 ||| NN
interactions  ||| S:32513 E:32526 ||| NNS
unique  ||| S:32526 E:32533 ||| JJ
to  ||| S:32533 E:32536 ||| TO
a  ||| S:32536 E:32538 ||| DT
given  ||| S:32538 E:32544 ||| VBN
set  ||| S:32544 E:32548 ||| VBN
of  ||| S:32548 E:32551 ||| IN
immunoassay  ||| S:32551 E:32563 ||| JJ
reagents ||| S:32563 E:32571 ||| NN
,  ||| S:32571 E:32573 ||| ,
can  ||| S:32573 E:32577 ||| MD
influence  ||| S:32577 E:32587 ||| VB
nonspecific  ||| S:32587 E:32599 ||| JJ
binding ||| S:32599 E:32606 ||| NN
.  ||| S:32606 E:32608 ||| .
The  ||| S:32608 E:32612 ||| DT
most  ||| S:32612 E:32617 ||| RBS
important  ||| S:32617 E:32627 ||| JJ
parameter  ||| S:32627 E:32637 ||| NN
when  ||| S:32637 E:32642 ||| WRB
selecting  ||| S:32642 E:32652 ||| VBG
a  ||| S:32652 E:32654 ||| DT
blocker  ||| S:32654 E:32662 ||| NN
is  ||| S:32662 E:32665 ||| VBZ
the  ||| S:32665 E:32669 ||| DT
signal ||| S:32669 E:32675 ||| NN
: ||| S:32675 E:32676 ||| :
noise  ||| S:32676 E:32682 ||| NN
ratio ||| S:32682 E:32687 ||| NN
,  ||| S:32687 E:32689 ||| ,
measured  ||| S:32689 E:32698 ||| VBN
as  ||| S:32698 E:32701 ||| IN
the  ||| S:32701 E:32705 ||| DT
signal  ||| S:32705 E:32712 ||| NN
obtained  ||| S:32712 E:32721 ||| VBN
with  ||| S:32721 E:32726 ||| IN
a  ||| S:32726 E:32728 ||| DT
tissue  ||| S:32728 E:32735 ||| NN
sample  ||| S:32735 E:32742 ||| NN
containing  ||| S:32742 E:32753 ||| VBG
the  ||| S:32753 E:32757 ||| DT
target  ||| S:32757 E:32764 ||| NN
analyte ||| S:32764 E:32771 ||| NN
,  ||| S:32771 E:32773 ||| ,
as  ||| S:32773 E:32776 ||| RB
compared  ||| S:32776 E:32785 ||| VBN
to  ||| S:32785 E:32788 ||| TO
that  ||| S:32788 E:32793 ||| DT
obtained  ||| S:32793 E:32802 ||| VBN
with  ||| S:32802 E:32807 ||| IN
a  ||| S:32807 E:32809 ||| DT
sample  ||| S:32809 E:32816 ||| NN
without  ||| S:32816 E:32824 ||| IN
the  ||| S:32824 E:32828 ||| DT
target  ||| S:32828 E:32835 ||| NN
analyte ||| S:32835 E:32842 ||| NN
.  ||| S:32842 E:32844 ||| .
Using  ||| S:32844 E:32850 ||| VBG
inadequate  ||| S:32850 E:32861 ||| JJ
amounts  ||| S:32861 E:32869 ||| NNS
of  ||| S:32869 E:32872 ||| IN
blocker  ||| S:32872 E:32880 ||| NN
will  ||| S:32880 E:32885 ||| MD
result  ||| S:32885 E:32892 ||| VB
in  ||| S:32892 E:32895 ||| IN
excessive  ||| S:32895 E:32905 ||| JJ
background  ||| S:32905 E:32916 ||| NN
staining  ||| S:32916 E:32925 ||| NNS
and  ||| S:32925 E:32929 ||| CC
a  ||| S:32929 E:32931 ||| DT
reduced  ||| S:32931 E:32939 ||| JJ
signal ||| S:32939 E:32945 ||| NN
: ||| S:32945 E:32946 ||| :
noise  ||| S:32946 E:32952 ||| NN
ratio ||| S:32952 E:32957 ||| NN
.  ||| S:32957 E:32959 ||| .
Using  ||| S:32959 E:32965 ||| VBG
excessive  ||| S:32965 E:32975 ||| JJ
concentrations  ||| S:32975 E:32990 ||| NNS
of  ||| S:32990 E:32993 ||| IN
blocker  ||| S:32993 E:33001 ||| NN
may  ||| S:33001 E:33005 ||| MD
mask  ||| S:33005 E:33010 ||| VB
antibody ||| S:33010 E:33018 ||| NN
: ||| S:33018 E:33019 ||| :
antigen  ||| S:33019 E:33027 ||| JJ
interactions  ||| S:33027 E:33040 ||| NNS
or  ||| S:33040 E:33043 ||| CC
inhibit  ||| S:33043 E:33051 ||| VB
the  ||| S:33051 E:33055 ||| DT
marker  ||| S:33055 E:33062 ||| JJ
enzyme ||| S:33062 E:33068 ||| NN
,  ||| S:33068 E:33070 ||| ,
again  ||| S:33070 E:33076 ||| RB
causing  ||| S:33076 E:33084 ||| VBG
a  ||| S:33084 E:33086 ||| DT
reduction  ||| S:33086 E:33096 ||| NN
of  ||| S:33096 E:33099 ||| IN
the  ||| S:33099 E:33103 ||| DT
signal ||| S:33103 E:33109 ||| NN
: ||| S:33109 E:33110 ||| :
noise  ||| S:33110 E:33116 ||| NN
ratio ||| S:33116 E:33121 ||| NN
.  ||| S:33121 E:33123 ||| .
When  ||| S:33123 E:33128 ||| WRB
developing  ||| S:33128 E:33139 ||| VBG
any  ||| S:33139 E:33143 ||| DT
new  ||| S:33143 E:33147 ||| JJ
immunoassay ||| S:33147 E:33158 ||| NN
,  ||| S:33158 E:33160 ||| ,
it  ||| S:33160 E:33163 ||| PRP
is  ||| S:33163 E:33166 ||| VBZ
important  ||| S:33166 E:33176 ||| JJ
to  ||| S:33176 E:33179 ||| TO
test  ||| S:33179 E:33184 ||| VB
several  ||| S:33184 E:33192 ||| JJ
different  ||| S:33192 E:33202 ||| JJ
blockers  ||| S:33202 E:33211 ||| NN
for  ||| S:33211 E:33215 ||| IN
the  ||| S:33215 E:33219 ||| DT
highest  ||| S:33219 E:33227 ||| JJS
signal ||| S:33227 E:33233 ||| NN
: ||| S:33233 E:33234 ||| :
noise  ||| S:33234 E:33240 ||| NN
ratio  ||| S:33240 E:33246 ||| NN
in  ||| S:33246 E:33249 ||| IN
the  ||| S:33249 E:33253 ||| DT
assay ||| S:33253 E:33258 ||| NN
.  ||| S:33258 E:33260 ||| .
No  ||| S:33260 E:33263 ||| DT
single  ||| S:33263 E:33270 ||| JJ
blocking  ||| S:33270 E:33279 ||| VBG
agent  ||| S:33279 E:33285 ||| NN
is  ||| S:33285 E:33288 ||| VBZ
ideal  ||| S:33288 E:33294 ||| VBN
for  ||| S:33294 E:33298 ||| IN
every  ||| S:33298 E:33304 ||| DT
occasion  ||| S:33304 E:33313 ||| NN
since  ||| S:33313 E:33319 ||| IN
each  ||| S:33319 E:33324 ||| DT
antibody-antigen  ||| S:33324 E:33341 ||| JJ
pair  ||| S:33341 E:33346 ||| NN
has  ||| S:33346 E:33350 ||| VBZ
unique  ||| S:33350 E:33357 ||| JJ
characteristics ||| S:33357 E:33372 ||| NNS
.  ||| S:33372 E:33374 ||| .
Agents  ||| S:33374 E:33381 ||| NNS
such  ||| S:33381 E:33386 ||| JJ
as  ||| S:33386 E:33389 ||| IN
nonfat  ||| S:33389 E:33396 ||| JJ
dry  ||| S:33396 E:33400 ||| JJ
milk  ||| S:33400 E:33405 ||| NN
and  ||| S:33405 E:33409 ||| CC
salmon  ||| S:33409 E:33416 ||| JJ
serum ||| S:33416 E:33421 ||| NN
,  ||| S:33421 E:33423 ||| ,
in  ||| S:33423 E:33426 ||| IN
addition  ||| S:33426 E:33435 ||| NN
to  ||| S:33435 E:33438 ||| TO
those  ||| S:33438 E:33444 ||| DT
mentioned  ||| S:33444 E:33454 ||| VBN
above ||| S:33454 E:33459 ||| IN
,  ||| S:33459 E:33461 ||| ,
may  ||| S:33461 E:33465 ||| MD
be  ||| S:33465 E:33468 ||| VB
used ||| S:33468 E:33472 ||| VBN
.  ||| S:33472 E:33476 ||| .
The  ||| S:34610 E:34614 ||| DT
present  ||| S:34614 E:34622 ||| JJ
MDS  ||| S:34622 E:34626 ||| NNP
diluent  ||| S:34626 E:34634 ||| NN
is  ||| S:34634 E:34637 ||| VBZ
hostile  ||| S:34637 E:34645 ||| JJ
to  ||| S:34645 E:34648 ||| TO
the  ||| S:34648 E:34652 ||| DT
stability  ||| S:34652 E:34662 ||| NN
of  ||| S:34662 E:34665 ||| IN
phosphorylated  ||| S:34665 E:34680 ||| JJ
antibodies ||| S:34680 E:34690 ||| NNS
,  ||| S:34690 E:34692 ||| ,
as  ||| S:34692 E:34695 ||| RB
seen  ||| S:34695 E:34700 ||| VBN
in  ||| S:34700 E:34703 ||| IN
FIG.  ||| S:34703 E:34708 ||| CD
4  ||| S:34708 E:34710 ||| CD
in  ||| S:34710 E:34713 ||| IN
the  ||| S:34713 E:34717 ||| DT
top  ||| S:34717 E:34721 ||| JJ
three  ||| S:34721 E:34727 ||| CD
frames  ||| S:34727 E:34734 ||| NNS
labeled  ||| S:34734 E:34750 ||| VBD
MDS  ||| S:34750 E:34754 ||| NNP
Diluent  ||| S:34754 E:34762 ||| NNP
Day  ||| S:34762 E:34766 ||| NNP
X  ||| S:34766 E:34775 ||| NNP
,  ||| S:34775 E:34777 ||| ,
where  ||| S:34777 E:34783 ||| WRB
X  ||| S:34783 E:34785 ||| NNP
is  ||| S:34785 E:34788 ||| VBZ
0  ||| S:34788 E:34790 ||| CD
in  ||| S:34790 E:34793 ||| IN
the  ||| S:34793 E:34797 ||| DT
first  ||| S:34797 E:34803 ||| JJ
frame ||| S:34803 E:34808 ||| NN
,  ||| S:34808 E:34810 ||| ,
and  ||| S:34810 E:34814 ||| CC
increases  ||| S:34814 E:34824 ||| NNS
with  ||| S:34824 E:34829 ||| IN
increasing  ||| S:34829 E:34840 ||| VBG
time  ||| S:34840 E:34845 ||| NN
in  ||| S:34845 E:34848 ||| IN
the  ||| S:34848 E:34852 ||| DT
diluent  ||| S:34852 E:34860 ||| NN
to  ||| S:34860 E:34863 ||| TO
14  ||| S:34863 E:34866 ||| CD
days  ||| S:34866 E:34871 ||| NNS
in  ||| S:34871 E:34874 ||| IN
the  ||| S:34874 E:34878 ||| DT
last  ||| S:34878 E:34883 ||| JJ
frame ||| S:34883 E:34888 ||| NN
.  ||| S:34888 E:34890 ||| .
By  ||| S:34890 E:34893 ||| IN
the  ||| S:34893 E:34897 ||| DT
last  ||| S:34897 E:34902 ||| JJ
frame  ||| S:34902 E:34908 ||| NN
( ||| S:34908 E:34909 ||| -LRB-
Day  ||| S:34909 E:34913 ||| NNP
14 ||| S:34913 E:34915 ||| CD
)  ||| S:34915 E:34917 ||| -RRB-
all  ||| S:34917 E:34921 ||| DT
antibody  ||| S:34921 E:34930 ||| NN
activity  ||| S:34930 E:34939 ||| NN
is  ||| S:34939 E:34942 ||| VBZ
gone  ||| S:34942 E:34947 ||| VBN
in  ||| S:34947 E:34950 ||| IN
the  ||| S:34950 E:34954 ||| DT
MDS  ||| S:34954 E:34958 ||| NNP
diluent ||| S:34958 E:34965 ||| NN
,  ||| S:34965 E:34967 ||| ,
whereas  ||| S:34967 E:34975 ||| VBG
in  ||| S:34975 E:34978 ||| IN
the  ||| S:34978 E:34982 ||| DT
TBMC  ||| S:34982 E:34987 ||| NNP
diluent  ||| S:34987 E:34995 ||| VBD
the  ||| S:34995 E:34999 ||| DT
LCA  ||| S:34999 E:35003 ||| NNP
antibody  ||| S:35003 E:35012 ||| NN
is  ||| S:35012 E:35015 ||| VBZ
still  ||| S:35015 E:35021 ||| RB
staining  ||| S:35021 E:35030 ||| VB
the  ||| S:35030 E:35034 ||| DT
tonsil  ||| S:35034 E:35041 ||| JJ
sections  ||| S:35041 E:35050 ||| NNS
well ||| S:35050 E:35054 ||| RB
.  ||| S:35054 E:35058 ||| .
In  ||| S:35238 E:35241 ||| IN
FIG.  ||| S:35241 E:35246 ||| CD
5 ||| S:35246 E:35247 ||| CD
,  ||| S:35247 E:35249 ||| ,
the  ||| S:35249 E:35253 ||| DT
top  ||| S:35253 E:35257 ||| JJ
three  ||| S:35257 E:35263 ||| CD
frames  ||| S:35263 E:35270 ||| NNS
show  ||| S:35270 E:35275 ||| VBP
the  ||| S:35275 E:35279 ||| DT
pERK  ||| S:35279 E:35284 ||| JJ
antibody  ||| S:35284 E:35293 ||| NN
diluted  ||| S:35293 E:35301 ||| VBN
in  ||| S:35301 E:35304 ||| IN
TBMC  ||| S:35304 E:35309 ||| NNP
diluent ||| S:35309 E:35316 ||| NN
,  ||| S:35316 E:35318 ||| ,
and  ||| S:35318 E:35322 ||| CC
in  ||| S:35322 E:35325 ||| IN
TBST  ||| S:35325 E:35330 ||| NNP
diluent  ||| S:35330 E:35338 ||| NNS
( ||| S:35338 E:35339 ||| -LRB-
bottom  ||| S:35339 E:35346 ||| JJ
three  ||| S:35346 E:35352 ||| CD
frames ||| S:35352 E:35358 ||| NNS
)  ||| S:35358 E:35360 ||| -RRB-
at  ||| S:35360 E:35363 ||| IN
time=0 ||| S:35363 E:35369 ||| NNP
,  ||| S:35369 E:35371 ||| ,
7  ||| S:35371 E:35373 ||| CD
days ||| S:35373 E:35377 ||| NNS
,  ||| S:35377 E:35379 ||| ,
and  ||| S:35379 E:35383 ||| CC
14  ||| S:35383 E:35386 ||| CD
days ||| S:35386 E:35390 ||| NNS
.  ||| S:35390 E:35392 ||| .
Stability  ||| S:35392 E:35402 ||| NN
in  ||| S:35402 E:35405 ||| IN
both  ||| S:35405 E:35410 ||| DT
diluents  ||| S:35410 E:35419 ||| NN
is  ||| S:35419 E:35422 ||| VBZ
apparent ||| S:35422 E:35430 ||| JJ
.  ||| S:35430 E:35432 ||| .
The  ||| S:35432 E:35436 ||| DT
sections  ||| S:35436 E:35445 ||| JJ
stained  ||| S:35445 E:35453 ||| NN
were  ||| S:35453 E:35458 ||| VBD
4  ||| S:35458 E:35460 ||| CD
um  ||| S:35460 E:35463 ||| JJ
breast  ||| S:35463 E:35470 ||| NN
carcinoma  ||| S:35470 E:35480 ||| NN
sections  ||| S:35480 E:35489 ||| NNS
sourced  ||| S:35489 E:35497 ||| VBN
from  ||| S:35497 E:35502 ||| IN
the  ||| S:35502 E:35506 ||| DT
in-house  ||| S:35506 E:35515 ||| JJ
Ventana  ||| S:35515 E:35523 ||| JJ
tissue  ||| S:35523 E:35530 ||| NN
bank ||| S:35530 E:35534 ||| NN
.  ||| S:35534 E:35536 ||| .
However ||| S:35536 E:35543 ||| RB
,  ||| S:35543 E:35545 ||| ,
those  ||| S:35545 E:35551 ||| DT
of  ||| S:35551 E:35554 ||| IN
ordinary  ||| S:35554 E:35563 ||| JJ
skill  ||| S:35563 E:35569 ||| NN
will  ||| S:35569 E:35574 ||| MD
appreciate  ||| S:35574 E:35585 ||| VB
that  ||| S:35585 E:35590 ||| IN
any  ||| S:35590 E:35594 ||| DT
breast  ||| S:35594 E:35601 ||| NN
carcinoma  ||| S:35601 E:35611 ||| NN
tissue  ||| S:35611 E:35618 ||| NN
expresses  ||| S:35618 E:35628 ||| VBZ
pERK ||| S:35628 E:35632 ||| JJ
,  ||| S:35632 E:35634 ||| ,
and  ||| S:35634 E:35638 ||| CC
so  ||| S:35638 E:35641 ||| RB
any  ||| S:35641 E:35645 ||| DT
breast  ||| S:35645 E:35652 ||| NN
tumor  ||| S:35652 E:35658 ||| NN
tissue  ||| S:35658 E:35665 ||| NN
may  ||| S:35665 E:35669 ||| MD
be  ||| S:35669 E:35672 ||| VB
used ||| S:35672 E:35676 ||| VBN
.  ||| S:35676 E:35679 ||| .
Quantum  ||| S:35736 E:35744 ||| NNP
Dots  ||| S:35744 E:35757 ||| NNPS
are  ||| S:35757 E:35761 ||| VBP
semiconductor  ||| S:35761 E:35775 ||| JJ
nanocrystal-based  ||| S:35775 E:35793 ||| JJ
fluorescent  ||| S:35793 E:35805 ||| JJ
tags  ||| S:35805 E:35810 ||| NNS
that  ||| S:35810 E:35815 ||| WDT
are  ||| S:35815 E:35819 ||| VBP
being  ||| S:35819 E:35825 ||| VBG
used  ||| S:35825 E:35830 ||| VBN
in  ||| S:35830 E:35833 ||| IN
life  ||| S:35833 E:35838 ||| NN
sciences  ||| S:35838 E:35847 ||| NN
research  ||| S:35847 E:35856 ||| NN
due  ||| S:35856 E:35860 ||| JJ
to  ||| S:35860 E:35863 ||| TO
their  ||| S:35863 E:35869 ||| PRP$
ability  ||| S:35869 E:35877 ||| NN
to  ||| S:35877 E:35880 ||| TO
emit  ||| S:35880 E:35885 ||| VB
narrow  ||| S:35885 E:35892 ||| JJ
frequencies  ||| S:35892 E:35904 ||| NN
of  ||| S:35904 E:35907 ||| IN
light  ||| S:35907 E:35913 ||| NN
when  ||| S:35913 E:35918 ||| WRB
appropriately  ||| S:35918 E:35932 ||| RB
excited ||| S:35932 E:35939 ||| VBN
.  ||| S:35939 E:35941 ||| .
They  ||| S:35941 E:35946 ||| PRP
can  ||| S:35946 E:35950 ||| MD
be  ||| S:35950 E:35953 ||| VB
conjugated  ||| S:35953 E:35964 ||| VBN
to  ||| S:35964 E:35967 ||| TO
biomolecules  ||| S:35967 E:35980 ||| VB
such  ||| S:35980 E:35985 ||| JJ
as  ||| S:35985 E:35988 ||| IN
haptens ||| S:35988 E:35995 ||| NN
,  ||| S:35995 E:35997 ||| ,
antibodies  ||| S:35997 E:36008 ||| NNS
or  ||| S:36008 E:36011 ||| CC
DNA  ||| S:36011 E:36015 ||| NNP
probes ||| S:36015 E:36021 ||| NNS
,  ||| S:36021 E:36023 ||| ,
and  ||| S:36023 E:36027 ||| CC
then  ||| S:36027 E:36032 ||| RB
bound  ||| S:36032 E:36038 ||| VBN
or  ||| S:36038 E:36041 ||| CC
hybridized  ||| S:36041 E:36052 ||| JJ
to  ||| S:36052 E:36055 ||| TO
their  ||| S:36055 E:36061 ||| PRP$
respective  ||| S:36061 E:36072 ||| JJ
biological  ||| S:36072 E:36083 ||| JJ
targets ||| S:36083 E:36090 ||| NNS
.  ||| S:36090 E:36094 ||| .
FIG.  ||| S:37058 E:37063 ||| CD
2  ||| S:37063 E:37065 ||| CD
shows  ||| S:37065 E:37071 ||| NNS
the  ||| S:37071 E:37075 ||| DT
effect  ||| S:37075 E:37082 ||| NN
casein  ||| S:37082 E:37089 ||| NN
seems  ||| S:37089 E:37095 ||| VBZ
to  ||| S:37095 E:37098 ||| TO
have  ||| S:37098 E:37103 ||| VB
in  ||| S:37103 E:37106 ||| IN
the  ||| S:37106 E:37110 ||| DT
TBMC  ||| S:37110 E:37115 ||| NNP
diluent ||| S:37115 E:37122 ||| NN
.  ||| S:37122 E:37124 ||| .
The  ||| S:37124 E:37128 ||| DT
figure  ||| S:37128 E:37135 ||| NN
shows  ||| S:37135 E:37141 ||| VBZ
a  ||| S:37141 E:37143 ||| DT
different  ||| S:37143 E:37153 ||| JJ
antibody  ||| S:37153 E:37162 ||| NN
anti-CD45  ||| S:37162 E:37172 ||| CD
antibody  ||| S:37172 E:37181 ||| NN
LCA  ||| S:37181 E:37185 ||| NNS
being  ||| S:37185 E:37191 ||| VBG
stained  ||| S:37191 E:37199 ||| NN
on  ||| S:37199 E:37202 ||| IN
tonsil  ||| S:37202 E:37209 ||| JJ
sections ||| S:37209 E:37217 ||| NNS
,  ||| S:37217 E:37219 ||| ,
and  ||| S:37219 E:37223 ||| CC
then  ||| S:37223 E:37228 ||| RB
being  ||| S:37228 E:37234 ||| VBG
detected  ||| S:37234 E:37243 ||| VBN
using  ||| S:37243 E:37249 ||| VBG
the  ||| S:37249 E:37253 ||| DT
same  ||| S:37253 E:37258 ||| JJ
QDot-Streptavidin  ||| S:37258 E:37276 ||| JJ
605  ||| S:37276 E:37280 ||| CD
conjugate ||| S:37280 E:37289 ||| NNS
.  ||| S:37289 E:37291 ||| .
This  ||| S:37291 E:37296 ||| DT
figure  ||| S:37296 E:37303 ||| NN
shows  ||| S:37303 E:37309 ||| NNS
that  ||| S:37309 E:37314 ||| IN
the  ||| S:37314 E:37318 ||| DT
blocking  ||| S:37318 E:37327 ||| VBG
proteins  ||| S:37327 E:37336 ||| NNS
behave  ||| S:37336 E:37343 ||| VBP
surprisingly  ||| S:37343 E:37356 ||| RB
differently  ||| S:37356 E:37368 ||| RB
regarding  ||| S:37368 E:37378 ||| VBG
stability  ||| S:37378 E:37388 ||| NN
of  ||| S:37388 E:37391 ||| IN
the  ||| S:37391 E:37395 ||| DT
diluent ||| S:37395 E:37402 ||| NN
.  ||| S:37402 E:37404 ||| .
For  ||| S:37404 E:37408 ||| IN
instance ||| S:37408 E:37416 ||| NN
,  ||| S:37416 E:37418 ||| ,
the  ||| S:37418 E:37422 ||| DT
signals  ||| S:37422 E:37430 ||| NNS
degrade  ||| S:37430 E:37438 ||| VBP
most  ||| S:37438 E:37443 ||| RBS
rapidly  ||| S:37443 E:37451 ||| RB
in  ||| S:37451 E:37454 ||| IN
BGG  ||| S:37454 E:37458 ||| NNP
( ||| S:37458 E:37459 ||| -LRB-
bovine  ||| S:37459 E:37466 ||| FW
gamma  ||| S:37466 E:37472 ||| FW
globulin ||| S:37472 E:37480 ||| FW
,  ||| S:37480 E:37482 ||| ,
bottom  ||| S:37482 E:37489 ||| JJ
right ||| S:37489 E:37494 ||| NN
) ||| S:37494 E:37495 ||| -RRB-
,  ||| S:37495 E:37497 ||| ,
then  ||| S:37497 E:37502 ||| RB
degrade  ||| S:37502 E:37510 ||| VBN
significantly  ||| S:37510 E:37524 ||| RB
in  ||| S:37524 E:37527 ||| IN
BSA  ||| S:37527 E:37531 ||| NNP
( ||| S:37531 E:37532 ||| -LRB-
bovine  ||| S:37532 E:37539 ||| FW
serum  ||| S:37539 E:37545 ||| FW
albumin ||| S:37545 E:37552 ||| FW
,  ||| S:37552 E:37554 ||| ,
top  ||| S:37554 E:37558 ||| JJ
right ||| S:37558 E:37563 ||| NN
)  ||| S:37563 E:37565 ||| -RRB-
then  ||| S:37565 E:37570 ||| RB
not  ||| S:37570 E:37574 ||| RB
at  ||| S:37574 E:37577 ||| IN
all  ||| S:37577 E:37581 ||| DT
in  ||| S:37581 E:37584 ||| IN
casein  ||| S:37584 E:37591 ||| NNS
( ||| S:37591 E:37592 ||| -LRB-
top  ||| S:37592 E:37596 ||| JJ
left ||| S:37596 E:37600 ||| NN
) ||| S:37600 E:37601 ||| -RRB-
.  ||| S:37601 E:37603 ||| .
These  ||| S:37603 E:37609 ||| DT
results  ||| S:37609 E:37617 ||| NNS
were  ||| S:37617 E:37622 ||| VBD
generated  ||| S:37622 E:37632 ||| VBN
at  ||| S:37632 E:37635 ||| IN
45  ||| S:37635 E:37644 ||| CD
C ||| S:37644 E:37645 ||| NNP
.  ||| S:37645 E:37649 ||| .
FIG.  ||| S:37649 E:37654 ||| CD
3  ||| S:37654 E:37656 ||| CD
is  ||| S:37656 E:37659 ||| VBZ
a  ||| S:37659 E:37661 ||| DT
longer  ||| S:37661 E:37668 ||| JJR
term  ||| S:37668 E:37673 ||| NN
( ||| S:37673 E:37674 ||| -LRB-
5  ||| S:37674 E:37676 ||| CD
days  ||| S:37676 E:37681 ||| NNS
versus  ||| S:37681 E:37688 ||| IN
two ||| S:37688 E:37691 ||| CD
)  ||| S:37691 E:37693 ||| -RRB-
and  ||| S:37693 E:37697 ||| CC
higher  ||| S:37697 E:37704 ||| JJR
temperature  ||| S:37704 E:37716 ||| NN
( ||| S:37716 E:37717 ||| -LRB-
45  ||| S:37717 E:37720 ||| CD
v.  ||| S:37720 E:37723 ||| CC
37 ||| S:37723 E:37725 ||| CD
)  ||| S:37725 E:37727 ||| -RRB-
test  ||| S:37727 E:37732 ||| NN
of  ||| S:37732 E:37735 ||| IN
the  ||| S:37735 E:37739 ||| DT
TBMC  ||| S:37739 E:37744 ||| NNP
diluent  ||| S:37744 E:37752 ||| VBD
discussed  ||| S:37752 E:37762 ||| VBN
in  ||| S:37762 E:37765 ||| IN
FIG.  ||| S:37765 E:37770 ||| CD
2 ||| S:37770 E:37771 ||| CD
.  ||| S:37771 E:37773 ||| .
The  ||| S:37773 E:37777 ||| DT
results  ||| S:37777 E:37785 ||| NNS
are  ||| S:37785 E:37789 ||| VBP
similar ||| S:37789 E:37796 ||| JJ
,  ||| S:37796 E:37798 ||| ,
with  ||| S:37798 E:37803 ||| IN
increased  ||| S:37803 E:37813 ||| JJ
degradation  ||| S:37813 E:37825 ||| NN
of  ||| S:37825 E:37828 ||| IN
signal  ||| S:37828 E:37835 ||| NN
over  ||| S:37835 E:37840 ||| IN
the  ||| S:37840 E:37844 ||| DT
extra  ||| S:37844 E:37850 ||| JJ
time  ||| S:37850 E:37855 ||| NN
and  ||| S:37855 E:37859 ||| CC
higher  ||| S:37859 E:37866 ||| JJR
temperatures  ||| S:37866 E:37879 ||| NNS
in  ||| S:37879 E:37882 ||| IN
all  ||| S:37882 E:37886 ||| DT
diluents ||| S:37886 E:37894 ||| NN
.  ||| S:37894 E:37898 ||| .
While  ||| S:37898 E:37904 ||| IN
the  ||| S:37904 E:37908 ||| DT
invention  ||| S:37908 E:37918 ||| NN
has  ||| S:37918 E:37922 ||| VBZ
been  ||| S:37922 E:37927 ||| VBN
described  ||| S:37927 E:37937 ||| VBN
with  ||| S:37937 E:37942 ||| IN
reference  ||| S:37942 E:37952 ||| NN
to  ||| S:37952 E:37955 ||| TO
an  ||| S:37955 E:37958 ||| DT
illustrative  ||| S:37958 E:37971 ||| JJ
embodiment ||| S:37971 E:37981 ||| NN
,  ||| S:37981 E:37983 ||| ,
it  ||| S:37983 E:37986 ||| PRP
will  ||| S:37986 E:37991 ||| MD
be  ||| S:37991 E:37994 ||| VB
understood  ||| S:37994 E:38005 ||| VBN
by  ||| S:38005 E:38008 ||| IN
those  ||| S:38008 E:38014 ||| DT
skilled  ||| S:38014 E:38022 ||| JJ
in  ||| S:38022 E:38025 ||| IN
the  ||| S:38025 E:38029 ||| DT
art  ||| S:38029 E:38033 ||| NN
that  ||| S:38033 E:38038 ||| IN
various  ||| S:38038 E:38046 ||| JJ
changes ||| S:38046 E:38053 ||| NNS
,  ||| S:38053 E:38055 ||| ,
omissions  ||| S:38055 E:38065 ||| NNS
and ||| S:38065 E:38068 ||| CC
/ ||| S:38068 E:38069 ||| NNP
or  ||| S:38069 E:38072 ||| CC
additions  ||| S:38072 E:38082 ||| NNS
may  ||| S:38082 E:38086 ||| MD
be  ||| S:38086 E:38089 ||| VB
made  ||| S:38089 E:38094 ||| VBN
and  ||| S:38094 E:38098 ||| CC
equivalents  ||| S:38098 E:38110 ||| NNS
may  ||| S:38110 E:38114 ||| MD
be  ||| S:38114 E:38117 ||| VB
substituted  ||| S:38117 E:38129 ||| VBN
for  ||| S:38129 E:38133 ||| IN
elements  ||| S:38133 E:38142 ||| NNS
thereof  ||| S:38142 E:38150 ||| RB
without  ||| S:38150 E:38158 ||| IN
departing  ||| S:38158 E:38168 ||| VBG
from  ||| S:38168 E:38173 ||| IN
the  ||| S:38173 E:38177 ||| DT
spirit  ||| S:38177 E:38184 ||| NN
and  ||| S:38184 E:38188 ||| CC
scope  ||| S:38188 E:38194 ||| NN
of  ||| S:38194 E:38197 ||| IN
the  ||| S:38197 E:38201 ||| DT
invention ||| S:38201 E:38210 ||| NN
.  ||| S:38210 E:38212 ||| .
In  ||| S:38212 E:38215 ||| IN
addition ||| S:38215 E:38223 ||| NN
,  ||| S:38223 E:38225 ||| ,
many  ||| S:38225 E:38230 ||| JJ
modifications  ||| S:38230 E:38244 ||| NNS
may  ||| S:38244 E:38248 ||| MD
be  ||| S:38248 E:38251 ||| VB
made  ||| S:38251 E:38256 ||| VBN
to  ||| S:38256 E:38259 ||| TO
adapt  ||| S:38259 E:38265 ||| VB
a  ||| S:38265 E:38267 ||| DT
particular  ||| S:38267 E:38278 ||| JJ
situation  ||| S:38278 E:38288 ||| NN
or  ||| S:38288 E:38291 ||| CC
material  ||| S:38291 E:38300 ||| NN
to  ||| S:38300 E:38303 ||| TO
the  ||| S:38303 E:38307 ||| DT
teachings  ||| S:38307 E:38317 ||| NN
of  ||| S:38317 E:38320 ||| IN
the  ||| S:38320 E:38324 ||| DT
invention  ||| S:38324 E:38334 ||| NN
without  ||| S:38334 E:38342 ||| IN
departing  ||| S:38342 E:38352 ||| VBG
from  ||| S:38352 E:38357 ||| IN
the  ||| S:38357 E:38361 ||| DT
scope  ||| S:38361 E:38367 ||| NN
thereof ||| S:38367 E:38374 ||| NN
.  ||| S:38374 E:38376 ||| .
Therefore ||| S:38376 E:38385 ||| RB
,  ||| S:38385 E:38387 ||| ,
it  ||| S:38387 E:38390 ||| PRP
is  ||| S:38390 E:38393 ||| VBZ
intended  ||| S:38393 E:38402 ||| VBN
that  ||| S:38402 E:38407 ||| IN
the  ||| S:38407 E:38411 ||| DT
invention  ||| S:38411 E:38421 ||| NN
not  ||| S:38421 E:38425 ||| RB
be  ||| S:38425 E:38428 ||| VB
limited  ||| S:38428 E:38436 ||| VBN
to  ||| S:38436 E:38439 ||| TO
the  ||| S:38439 E:38443 ||| DT
particular  ||| S:38443 E:38454 ||| JJ
embodiments  ||| S:38454 E:38466 ||| NNS
disclosed  ||| S:38466 E:38476 ||| VBN
as  ||| S:38476 E:38479 ||| IN
the  ||| S:38479 E:38483 ||| DT
best  ||| S:38483 E:38488 ||| JJS
mode  ||| S:38488 E:38493 ||| NN
contemplated  ||| S:38493 E:38506 ||| VBN
for  ||| S:38506 E:38510 ||| IN
carrying  ||| S:38510 E:38519 ||| VBG
out  ||| S:38519 E:38523 ||| RP
this  ||| S:38523 E:38528 ||| DT
invention ||| S:38528 E:38537 ||| NN
,  ||| S:38537 E:38539 ||| ,
but  ||| S:38539 E:38543 ||| CC
that  ||| S:38543 E:38548 ||| IN
the  ||| S:38548 E:38552 ||| DT
invention  ||| S:38552 E:38562 ||| NN
will  ||| S:38562 E:38567 ||| MD
include  ||| S:38567 E:38575 ||| VB
all  ||| S:38575 E:38579 ||| DT
embodiments  ||| S:38579 E:38591 ||| NN
falling  ||| S:38591 E:38599 ||| VBG
within  ||| S:38599 E:38606 ||| IN
the  ||| S:38606 E:38610 ||| DT
scope  ||| S:38610 E:38616 ||| NN
of  ||| S:38616 E:38619 ||| IN
the  ||| S:38619 E:38623 ||| DT
appended  ||| S:38623 E:38632 ||| JJ
claims ||| S:38632 E:38638 ||| NNS
.  ||| S:38638 E:38643 ||| .
We  ||| S:38643 E:38646 ||| PRP
claim ||| S:38646 E:38651 ||| VBP
:  ||| S:38651 E:38656 ||| :
1 ||| S:38656 E:38657 ||| LS
.  ||| S:38657 E:38659 ||| .
A  ||| S:38659 E:38661 ||| DT
diluent  ||| S:38661 E:38669 ||| NN
for  ||| S:38669 E:38673 ||| IN
stabilizing  ||| S:38673 E:38685 ||| VBG
biomolecules ||| S:38685 E:38697 ||| NN
,  ||| S:38697 E:38699 ||| ,
comprising  ||| S:38699 E:38710 ||| VBG
Tris  ||| S:38710 E:38715 ||| NNP
and  ||| S:38715 E:38719 ||| CC
a  ||| S:38719 E:38721 ||| DT
polyhydroxy  ||| S:38721 E:38733 ||| JJ
carbohydrate  ||| S:38733 E:38746 ||| NNS
selected  ||| S:38746 E:38755 ||| VBN
from  ||| S:38755 E:38760 ||| IN
the  ||| S:38760 E:38764 ||| DT
group  ||| S:38764 E:38770 ||| NN
consisting  ||| S:38770 E:38781 ||| VBG
of  ||| S:38781 E:38784 ||| IN
mannitol  ||| S:38784 E:38793 ||| NN
and  ||| S:38793 E:38797 ||| CC
trehalose ||| S:38797 E:38806 ||| NN
.  ||| S:38806 E:38812 ||| .
2 ||| S:38812 E:38813 ||| LS
.  ||| S:38813 E:38815 ||| .
The  ||| S:38815 E:38819 ||| DT
diluent  ||| S:38819 E:38827 ||| NN
of  ||| S:38827 E:38830 ||| IN
claim  ||| S:38830 E:38836 ||| NN
1  ||| S:38836 E:38838 ||| CD
wherein  ||| S:38838 E:38846 ||| JJ
casein  ||| S:38846 E:38853 ||| NN
is  ||| S:38853 E:38856 ||| VBZ
optionally  ||| S:38856 E:38867 ||| VBN
added  ||| S:38867 E:38873 ||| VBN
as  ||| S:38873 E:38876 ||| IN
a  ||| S:38876 E:38878 ||| DT
background  ||| S:38878 E:38889 ||| NN
blocking  ||| S:38889 E:38898 ||| VBG
protein ||| S:38898 E:38905 ||| NN
.  ||| S:38905 E:38911 ||| .
